[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2662
1. Poikonen E, Lyytikäinen O, Anttila VJ, Koivula I, Lumio J, Kotilainen P, Syrjälä H, Ruutu P: Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis; 2010;10:312
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systematic fluconazole prophylaxis was implemented for premature neonates, patients with acute leukemias and liver transplant patients.
  • CONCLUSION: The dominant proportion of C. albicans remained stable, but C. glabrata was the most frequent non-albicans species.
  • The proportion of C. glabrata had increased from our previous study period in the presence of increasing use of fluconazole.

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hosp Infect. 2002 Jan;50(1):56-65 [11825053.001]
  • [Cites] Scand J Infect Dis. 2009;41(8):590-6 [19488931.001]
  • [Cites] Clin Infect Dis. 2002 Jul 15;35(2):e14-9 [12087538.001]
  • [Cites] Clin Infect Dis. 2002 Sep 1;35(5):627-30 [12173140.001]
  • [Cites] J Hosp Infect. 2002 Aug;51(4):297-304 [12183145.001]
  • [Cites] J Clin Microbiol. 2002 Sep;40(9):3489-92 [12202600.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):767-74 [12461585.001]
  • [Cites] Emerg Infect Dis. 2003 Aug;9(8):985-90 [12967498.001]
  • [Cites] Clin Infect Dis. 2003 Nov 1;37(9):1172-7 [14557960.001]
  • [Cites] Clin Infect Dis. 2004 Feb 1;38(3):311-20 [14727199.001]
  • [Cites] Clin Microbiol Infect. 2004 Mar;10 Suppl 1:11-23 [14748799.001]
  • [Cites] J Clin Microbiol. 2004 Apr;42(4):1519-27 [15070998.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):323-30 [15024623.001]
  • [Cites] Clin Infect Dis. 2004 Aug 1;39(3):309-17 [15306996.001]
  • [Cites] Am J Med. 1996 Jun;100(6):617-23 [8678081.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1996 Dec;15(12):909-12 [9031872.001]
  • [Cites] Clin Infect Dis. 1997 Jun;24(6):1122-8 [9195068.001]
  • [Cites] Diagn Microbiol Infect Dis. 1998 Feb;30(2):121-9 [9554180.001]
  • [Cites] Clin Infect Dis. 1998 Oct;27(4):781-8 [9798034.001]
  • [Cites] Clin Infect Dis. 1998 Nov;27(5):1138-47 [9827260.001]
  • [Cites] J Clin Microbiol. 1999 Mar;37(3):531-7 [9986807.001]
  • [Cites] Clin Infect Dis. 1999 Aug;29(2):239-44 [10476719.001]
  • [Cites] Clin Infect Dis. 1999 Nov;29(5):1164-70 [10524958.001]
  • [Cites] J Clin Microbiol. 2005 Apr;43(4):1829-35 [15815004.001]
  • [Cites] J Clin Microbiol. 2005 Jun;43(6):2729-35 [15956390.001]
  • [Cites] Infect Control Hosp Epidemiol. 2005 Jun;26(6):540-7 [16018429.001]
  • [Cites] Infect Control Hosp Epidemiol. 2005 Jun;26(6):548-52 [16018430.001]
  • [Cites] J Antimicrob Chemother. 2005 Sep;56(3):532-7 [16040623.001]
  • [Cites] Clin Infect Dis. 2005 Nov 1;41(9):1232-9 [16206095.001]
  • [Cites] J Clin Microbiol. 2006 Jun;44(6):1977-81 [16757587.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):474-7 [16757503.001]
  • [Cites] Emerg Infect Dis. 2006 Oct;12(10):1508-16 [17176564.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):541-7 [17569999.001]
  • [Cites] Clin Microbiol Infect. 2008 May;14(5):487-94 [18294241.001]
  • [Cites] Clin Infect Dis. 2008 Jul 15;47(2):e17-24 [18549311.001]
  • [Cites] Clin Infect Dis. 2009 Jun 15;48(12):1695-703 [19441981.001]
  • [Cites] J Clin Microbiol. 2002 Apr;40(4):1298-302 [11923348.001]
  • (PMID = 21029444.001).
  • [ISSN] 1471-2334
  • [Journal-full-title] BMC infectious diseases
  • [ISO-abbreviation] BMC Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 8VZV102JFY / Fluconazole
  • [Other-IDs] NLM/ PMC2988049
  •  go-up   go-down


2. Galstian GM, Kesel'man SA, Gorodetskiĭ VM, Aleksanian MZh, Kulikov SM, Gemdzhian EG, Parovichnikova EN, Savchenko VG, Vorob'ev AI: [Combined chemotherapy for hemoblastoses and therapy for acute respiratory failure in intensive care conditions]. Ter Arkh; 2009;81(12):37-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined chemotherapy for hemoblastoses and therapy for acute respiratory failure in intensive care conditions].
  • AIM: To study the efficiency of polychemotherapy (PCT) for hemoblastoses in acute respiratory failure (ARP).
  • 1) 40 patients with acute leukemia (AL);.
  • RESULTS: The duration of lung lesion in leukemia was less than that in myeloma and lymphomas (2.5 +/- 5.3 versus 12.8 +/- 30.6 and 21 +/- 10.2 days, respectively).
  • In the patients with leukemia and lymphomas, PCT was initiated earlier than in those with myeloma (1.5 +/- 0.5 versus 1.75 +/- 3.1 and 8.3 +/- 10.9 days, respectively).
  • The groups did not differ in disease severity.
  • Sepsis was encountered twice more frequently in lymphomas and myeloma, and septic shock was 4 times more commonly in leukemias.
  • In myeloma, bacteremia was seen more frequently than in leukemia (50 and 10%; p = 0.024); serum procalcitonin was > 10 ng/ml (100 and 35%); p = 0.028).
  • In leukemias, lymphomas, and myeloma, 28-day survival was 60, 60, and 75%, respectively.
  • The baseline APACHE II disease severity, the degree of hypoxemia, and the presence and duration of agranulocytosis did not determine prognosis.
  • [MeSH-minor] APACHE. Acute Disease. Adolescent. Adult. Aged. Female. Humans. Leukemia / complications. Leukemia / drug therapy. Leukemia / epidemiology. Lymphoma / complications. Lymphoma / drug therapy. Lymphoma / epidemiology. Male. Medical Records. Middle Aged. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Multiple Myeloma / epidemiology. Prognosis. Regression Analysis. Respiratory Therapy / methods. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Critical Care.
  • MedlinePlus Health Information. consumer health - Respiratory Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20481047.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


3. Erbey F, Bayram I, Yilma S, Tanyeli A: Imipenem in the treatment of febrile neutropenic children. Asian Pac J Cancer Prev; 2009;10(5):921-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the patients, 10 (41.7%) had solid tumors, while 14 (58.3%) were diagnosed to have acute leukemia.
  • The mean duration of neutropenia was 6.3 -/+ 1.4 (4-8) days in patients with solid tumors, and 9.3 -/+ 7.4 (3-25) days in the group with leukemia.
  • Average time of stay in hospital was 9.0 -/+ 4.1 (4-20) days for patients with solid tumors, and 14.4 -/+ 10.6 (4-33) days for patients with leukemia.
  • FN duration was observed to be significantly longer in patients with an ANC of less than 200/mm3, and in children who were not in remission for the underlying malignant disease.
  • In addition, average time of stay in hospital was observed to be significantly longer in patients who were not in remission for the underlying malign disease.

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104991.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 71OTZ9ZE0A / Imipenem
  •  go-up   go-down


Advertisement
4. Haltrich I, Csóka M, Kovács G, Fekete G: [Cytogenetic and FISH findings are complementary in childhood ALL]. Magy Onkol; 2008 Sep;52(3):283-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] A hagyományos citogenetika és a FISH egymást jól kiegészíto vizsgálatok gyermekkori akut limfoid leukémiában.
  • Primary genetic abnormalities of leukemia cells have important prognostic significance in childhood acute leukemia.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 21. Gene Rearrangement. In Situ Hybridization, Fluorescence. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chromosome Banding. Core Binding Factor Alpha 2 Subunit / genetics. Female. Fusion Proteins, bcr-abl / genetics. Gene Deletion. Histone-Lysine N-Methyltransferase. Humans. Interphase. Karyotyping / methods. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics. Risk Factors. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845499.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


5. Najima Y, Ohashi K, Kawamura M, Onozuka Y, Yamaguchi T, Akiyama H, Sakamaki H: Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia. Int J Hematol; 2010 May;91(4):636-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia.
  • Recent studies have shown that high BAALC expression predicts an adverse prognosis and may define an important risk factor in acute myeloid leukemia patients with normal karyotype.
  • We performed, using real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR), the molecular analysis of BAALC gene as a possible minimal residual disease (MRD) marker in 45 patients with newly diagnosed acute leukemia.
  • Quantitation of BAALC gene expression made it possible to assess MRD in patients with CD34-positive acute leukemia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / mortality. Neoplasm Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / metabolism. Disease-Free Survival. Female. Gene Expression Regulation, Leukemic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm, Residual / genetics. Neoplasm, Residual / mortality. Predictive Value of Tests. Prognosis. RNA, Messenger / genetics. Risk Factors. Translocation, Genetic. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Mar 1;101(5):1698-704 [12406915.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1613-8 [12750167.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1416-24 [15746041.001]
  • [Cites] Exp Hematol. 2003 Nov;31(11):1051-6 [14585369.001]
  • [Cites] Leuk Lymphoma. 2004 Sep;45(9):1803-8 [15223639.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Leukemia. 2006 Jun;20(6):1103-8 [16541144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13901-6 [11707601.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4714-20 [16954520.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):106-14 [17255787.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S77-8 [15124683.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leukemia. 2002 Oct;16(10):2115-21 [12357365.001]
  • [Cites] Semin Hematol. 2003 Apr;40(2 Suppl 2):37-41 [12783374.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5371-9 [18378853.001]
  • (PMID = 20376583.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / BAALC protein, human; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


6. Aktas D, Tuncbilek E: Myelodysplastic syndrome associated with monosomy 7 in childhood: a retrospective study. Cancer Genet Cytogenet; 2006 Nov;171(1):72-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis, peripheral cytopenia, and dysplastic changes in the bone marrow.
  • Monosomy 7 or partial loss of 7q is a common cytogenetic abnormality in MDS patients and is associated with poor prognosis.
  • Five MDS patients with monosomy 7 progressed to acute leukemia: three cases transformed into acute myelogenous leukemia (AML) in a mean time of only 4.6 months and two cases into acute lymphoblastic leukemia (ALL) in a mean time of 9 months.
  • [MeSH-minor] Acute Disease. Child. Child, Preschool. Disease Progression. Female. Humans. Infant. Karyotyping. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Male. Prognosis. Retrospective Studies


7. Pasmant E, Sabbagh A, Hanna N, Masliah-Planchon J, Jolly E, Goussard P, Ballerini P, Cartault F, Barbarot S, Landman-Parker J, Soufir N, Parfait B, Vidaud M, Wolkenstein P, Vidaud D, France RN: SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype. J Med Genet; 2009 Jul;46(7):425-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.
  • OBJECTIVE: Germline loss-of-function mutations in the SPRED1 gene have recently been identified in patients fulfilling the National Institutes of Health (NIH) diagnostic criteria for neurofibromatosis type 1 (NF1) but with no NF1 (neurofibromin 1) mutation found, suggesting a neurofibromatosis type 1-like syndrome.
  • METHODS: 61 index cases with NF1 clinical diagnosis but no identifiable NF1 mutation were screened for SPRED1 mutation.
  • It is noteworthy that one patient with the p.Arg16Stop mutation developed a monoblastic acute leukaemia.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Mutational Analysis. Female. Gene Dosage. Genetic Predisposition to Disease. Humans. Male. Middle Aged. Pedigree


8. Tefferi A: JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma; 2008 Mar;49(3):388-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The Janus family of non-receptor tyrosine kinases (JAK1, JAK2, JAK3 and tyrosine kinase 2) transduces signals downstream of type I and II cytokine receptors via signal transducers and activators of transcription (STATs).
  • JAK3 is important in lymphoid and JAK2 in myeloid cell proliferation and differentiation.
  • ETV6-JAK2, PCM1-JAK2, BCR-JAK2) mutations have respectively been described in acute megakaryocytic leukemia and acute leukemia/chronic myeloid malignancies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297515.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Thrombopoietin; 0 / STAT Transcription Factors; 143641-95-6 / MPL protein, human; EC 2.7.10.2 / Janus Kinase 2; EC 2.7.10.2 / Janus Kinase 3
  • [Number-of-references] 167
  •  go-up   go-down


9. Pautas C, Merabet F, Thomas X, Raffoux E, Gardin C, Corm S, Bourhis JH, Reman O, Turlure P, Contentin N, de Revel T, Rousselot P, Preudhomme C, Bordessoule D, Fenaux P, Terré C, Michallet M, Dombret H, Chevret S, Castaigne S: Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol; 2010 Feb 10;28(5):808-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study.
  • PURPOSE In patients with acute myeloid leukemia (AML), induction chemotherapy is based on standard doses of anthracyclines and cytarabine.
  • PATIENTS AND METHODS In this randomized Acute Leukemia French Association 9801 (ALFA-9801) study, high doses of daunorubicin (DNR; 80 mg/m(2)/d x 3 days) or idarubicin (IDA4; 12 mg/m(2)/d x 4 days) were compared with standard doses of idarubicin (IDA3; 12 mg/m(2)/d x 3 days) for remission induction in patients age 50 to 70 years, with an event-free survival (EFS) end point.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Aged. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Idarubicin / administration & dosage. Interleukin-2 / administration & dosage. Interleukin-2 / analogs & derivatives. Kaplan-Meier Estimate. Male. Middle Aged. Proportional Hazards Models. Recombinant Proteins / administration & dosage. Recurrence. Risk Assessment. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20048183.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Recombinant Proteins; M89N0Q7EQR / aldesleukin; ZRP63D75JW / Idarubicin; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. Patton GW, Stephens R, Sidorov IA, Xiao X, Lempicki RA, Dimitrov DS, Shoemaker RH, Tudor G: Transcriptomic response to differentiation induction. BMC Bioinformatics; 2006 Feb 17;7:81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We applied a transcriptomics analysis tool to elucidate the underlying pathways of leukocyte maturation at the genomic level in an established cellular model of leukemia by examining time-course data in two subclones of U-937 cells.
  • Leukemias such as Acute Promyelocytic Leukemia (APL) are characterized by a block in the hematopoietic stem cell maturation program at a point when expansion of clones which should be destined to mature into terminally-differentiated effector cells get locked into endless proliferation with few cells reaching maturation.
  • Treatment with retinoic acid, depending on the precise genomic abnormality, often releases the responsible promyelocytes from this blockade but clinically can yield adverse sequellae in terms of potentially lethal side effects, referred to as retinoic acid syndrome.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2000 Jan 1;28(1):308-10 [10592257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):3826-31 [11274400.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1877-80 [12200713.001]
  • [Cites] Math Biosci. 2003 Feb;181(2):209-21 [12445762.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9608-13 [12869696.001]
  • [Cites] BMC Bioinformatics. 2002 Aug 23;3:22 [12194703.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3727-36 [12893766.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D3-22 [14681349.001]
  • [Cites] World J Gastroenterol. 2004 Apr 15;10(8):1082-7 [15069703.001]
  • [Cites] Nucleic Acids Res. 2004 Jul 1;32(Web Server issue):W213-6 [15215383.001]
  • [Cites] Mutat Res. 2004 Jul 13;551(1-2):51-64 [15225581.001]
  • [Cites] Int J Cancer. 1976 May 15;17(5):565-77 [178611.001]
  • [Cites] J Leukoc Biol. 1991 Aug;50(2):109-22 [1649238.001]
  • [Cites] Genes Dev. 1994 Apr 15;8(8):869-84 [7523245.001]
  • [Cites] Science. 1995 Oct 20;270(5235):467-70 [7569999.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Science. 1999 Apr 23;284(5414):606-9 [10213677.001]
  • [Cites] Oncogene. 2005 May 5;24(20):3358-68 [15735696.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1427-30 [10688781.001]
  • (PMID = 16503971.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CO / N01-CO-56000; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ PMC1395336
  •  go-up   go-down


11. Kiyoi H, Naoe T: Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int J Hematol; 2006 May;83(4):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
  • FLT3 mutations are the most frequent genetic alterations so far reported in acute myeloid leukemia and are involved in the signaling pathway of autonomous proliferation and differentiation block in leukemia cells.
  • However, because high-dose chemotherapy and stem cell transplantation cannot overcome the adverse effects of FLT3 mutations, the development of FLT3 kinase inhibitors is expected to produce a more efficacious therapeutic strategy for leukemia therapy.
  • [MeSH-major] Gene Expression Regulation, Leukemic / genetics. Leukemia, Myeloid, Acute / genetics. Mutation. Signal Transduction / genetics. fms-Like Tyrosine Kinase 3 / genetics
  • [MeSH-minor] Acute Disease. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Proliferation / drug effects. Drug Design. Enzyme Activation / drug effects. Enzyme Activation / genetics. Humans. Leukocytosis / enzymology. Leukocytosis / genetics. Leukocytosis / therapy. Prognosis. Protein Kinase Inhibitors / chemistry. Protein Kinase Inhibitors / therapeutic use. Protein Structure, Tertiary / drug effects. Protein Structure, Tertiary / genetics. Receptor Protein-Tyrosine Kinases / antagonists & inhibitors. Receptor Protein-Tyrosine Kinases / genetics. Receptor Protein-Tyrosine Kinases / metabolism. Risk Factors. Stem Cell Transplantation


12. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW: The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood; 2005 Nov 15;106(10):3377-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
  • We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL).
  • We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45).
  • These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.


13. Kuznetsova NR, Gaenko GP, Khaĭdukov SV, Bovin NV, Vodovozova EL: [The influence of carbohydrate ligands on the cytotoxicity of liposomes bearing a methotrexate-diglyceride conjugate in human acute leukemia cell cultures]. Bioorg Khim; 2009 Jul-Aug;35(4):542-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The influence of carbohydrate ligands on the cytotoxicity of liposomes bearing a methotrexate-diglyceride conjugate in human acute leukemia cell cultures].
  • We had previously shown in vitro using human acute leukemia cells with various sensitivity to MTX (T-lymphoblastic CCRF-CEM line and resistant CEM/MTX subline) that MTX incorporation into liposomes as a lipophilic prodrug, diglyceride conjugate (MTX-DG), allows for the overcoming of cell resistance due to the impaired active transmembrane transport.
  • In this work, we have studied the profile of binding with carbohydrates of the cell lines mentioned using carbohydrate fluorescent probes (poly(acryl amide) conjugates).
  • The cytotoxicity of MTX-DG liposomes equipped with the SiaLe(x) ligand toward the sensitive CCRF-CEM cell culture was demonstrated to be 3.5 times higher than that of MTX-DG liposomes bearing the control inactive pentaol.
  • [MeSH-minor] Biological Transport / drug effects. Cell Culture Techniques. Cell Line, Tumor. Cell Membrane / metabolism. Cell Survival / drug effects. Drug Screening Assays, Antitumor. Flow Cytometry. Fluorescent Dyes. Humans. Ligands. Lipids / chemistry. Liposomes

  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. POLYACRYLAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19928057.001).
  • [ISSN] 0132-3423
  • [Journal-full-title] Bioorganicheskaia khimiia
  • [ISO-abbreviation] Bioorg. Khim.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Antimetabolites, Antineoplastic; 0 / Diglycerides; 0 / Fluorescent Dyes; 0 / Ligands; 0 / Lipids; 0 / Liposomes; 9003-05-8 / polyacrylamide; ADK3G923Z3 / diolein; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


14. Biswas S, Chakrabarti S, Chakraborty J, Paul PC, Konar A, Das S: Childhood acute leukemia in West Bengal, India with an emphasis on uncommon clinical features. Asian Pac J Cancer Prev; 2009;10(5):903-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute leukemia in West Bengal, India with an emphasis on uncommon clinical features.
  • Leukemias are the commonest childhood malignancy in West Bengal.
  • This study was undertaken on 75 children at NRS Medical College, West Bengal to determine the distribution of signs and symptoms of leukemia and to identify unusual clinical features.
  • Acute lymphoblastic leukaemia (ALL, 72%) was the commonest followed by acute myeloid leukaemia (AML, 18.7%).
  • Uncommon clinical presentations lead to delay in diagnosis in some cases.
  • Awareness of uncommon signs and symptoms of childhood leukemia together with laboratory tests may help in earlier diagnosis and proper management of the patients.
  • [MeSH-major] Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Asian Pac J Cancer Prev. 2010;11(1):267-8 [20593969.001]
  • (PMID = 20104987.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


15. Dekking E, van der Velden VH, Böttcher S, Brüggemann M, Sonneveld E, Koning-Goedheer A, Boeckx N, Lucio P, Sedek L, Szczepański T, Kalina T, Kovac M, Evans P, Hoogeveen PG, Flores-Montero J, Orfao A, Comans-Bitter WM, Staal FJ, van Dongen JJ, EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708): Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay. Best Pract Res Clin Haematol; 2010 Sep;23(3):333-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of fusion genes at the protein level in leukemia patients via the flow cytometric immunobead assay.
  • Nowadays, the presence of specific genetic aberrations is progressively used for classification and treatment stratification, because acute leukemias with the same oncogenetic aberration generally form a clinically and diagnostically homogenous disease entity with comparable prognosis.
  • Many oncogenetic aberrations in acute leukemias result in a fusion gene, which is transcribed into fusion transcripts and translated into fusion proteins, which are assumed to play a critical role in the oncogenetic process.
  • Therefore we developed a flow cytometric immunobead assay for detection of fusion proteins in lysates of leukemia cell samples by use of a bead-bound catching antibody against one side of the fusion protein and fluorochrome-conjugated detection antibody.
  • The novel immunobead assay will enable fast and easy classification of acute leukemia patients that express fusion proteins.
  • [MeSH-major] Flow Cytometry / methods. Leukemia / genetics. Oncogene Proteins, Fusion / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Ltd.
  • (PMID = 21123134.001).
  • [ISSN] 1532-1924
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


16. Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, Choudhry VP, Saxena R: Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl Thromb Hemost; 2007 Jul;13(3):292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy.
  • Between January 2001 and December 2003, 67 patients with acute leukemia were evaluated prospectively for hemostatic abnormality at presentation, of which 43 (64.2%) had acute lymphoblastic leukemia and 24 (35.8%) had acute myelogenous leukemia.
  • Thrombocytopenia was present in 57 patients (85%), and 33(49.3%) had some abnormality of global coagulation markers.
  • Disseminated intravascular coagulation was more often associated with bleeding manifestations in acute myelogenous leukemia cases than in acute lymphoblastic leukemia cases.
  • It is recommended that all patients with leukemia be investigated for disseminated intravascular coagulation at presentation.
  • [MeSH-major] Disseminated Intravascular Coagulation / diagnosis. Disseminated Intravascular Coagulation / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17636191.001).
  • [ISSN] 1076-0296
  • [Journal-full-title] Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • [ISO-abbreviation] Clin. Appl. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; BFM-86 protocol
  •  go-up   go-down


17. Svahn BM, Alvin O, Ringdén O, Gardulf A, Remberger M: Costs of allogeneic hematopoietic stem cell transplantation. Transplantation; 2006 Jul 27;82(2):147-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Costs of allogeneic hematopoietic stem cell transplantation.
  • BACKGROUND: This study aims to determine the total costs after allogeneic hematopoietic stem cell transplantation (ASCT) and factors associated with increases or decreases in costs.
  • The total costs during the first year were higher in patients with acute graft-versus-host disease grades III-IV (relative hazards [RH] 1.35, P = 0.003), bacteremia (RH 1.33, P = 0.005), veno-occlusive disease of the liver (RH 1.32, P = 0.005), prophylaxis with granulocyte colony-stimulating factor (G-CSF; RH 1.31, P = 0.01), acute leukemia (RH 1.32, P = 0.008), and treatment in hospital instead of at home (RH 1.20, P < 0.07).
  • CONCLUSION: Higher costs of ASCT were associated with retransplantation, acute leukemia, G-CSF prophylaxis, hospital care, myeloablative conditioning, and major transplant-related complications.
  • [MeSH-major] Neoplasms / therapy. Stem Cell Transplantation / economics

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858272.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Shman TV, Belevtsev MV, Buglova SE: [Drug sensitivity of tumor cells in varieties of acute childhood leukemia]. Vopr Onkol; 2005;51(5):558-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
  • Drug sensitivity of tumor cells was studied in 154 children diagnosed with acute leukemia.
  • Cellular sensitivity in acute lymphoblastic leukemia (ALL) was higher than in acute myeloid one (AML), while T-line ALL cells were more sensitive to dexamethasone than those of B-line.
  • It was suggested that lower drug sensitivity of ALL cells at the earlier stages of cell differentiation was due to their reduced susceptibility to apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Leukemia, Myeloid, Acute / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16756010.001).
  • [ISSN] 0507-3758
  • [Journal-full-title] Voprosy onkologii
  • [ISO-abbreviation] Vopr Onkol
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7006-34-0 / Asparagine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


19. Leung E, Teshima I, Ye C, Grant R, Abdelhaleem M: A der(19)t(12;19)(q12;p13.3) in a case of pediatric acute leukemia with unusual immunophenotype. Cancer Genet Cytogenet; 2005 Mar;157(2):164-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A der(19)t(12;19)(q12;p13.3) in a case of pediatric acute leukemia with unusual immunophenotype.
  • We describe a case of acute leukemia in a child with an unusual immunophenotype and a novel cytogenetic abnormality.
  • The leukemia blasts expressed myeloid, natural killer and B-lineage associated antigens.
  • Cytogenetics showed the presence of a novel unbalanced chromosomal translocation, der(19)t(12;19)(q12;p13.3).
  • The differential diagnosis of the immunophenotype and the potential fusion genes are discussed.
  • [MeSH-major] Chromosomes, Human, Pair 12. Chromosomes, Human, Pair 19. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Female. Humans. Spectral Karyotyping. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721640.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Chim CS, Wong AS, Kwong YL: Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias. Am J Hematol; 2005 Dec;80(4):282-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of the CIP/KIP cell-cycle control pathway in acute leukemias.
  • Dysregulation of the cell cycle is important in oncogenesis.
  • We analyzed the potential inactivation of the CIP/KIP family of the cyclin E/CDK/RB pathway by gene promoter hypermethylation in leukemias.
  • The methylation-specific polymerase chain reaction (MSP) with primers for methylated (M-MSP) and unmethylated (U-MSP) alleles of the p21, p27, and p57 genes was used to study five leukemic cell lines, 50 acute myeloid leukemia (AML) samples, and 25 acute lymphoblastic leukemia (ALL) samples. p21 was hemizygously methylated in Raji and Jurkat but remained unmethylated in U937, HL60, and NB4. p27 was hemizygously methylated in Raji but unmethylated in the other cell lines. p57 was completely methylated in Raji and NB4, hemizygously methylated in U937, and unmethylated in HL60 and Jurkat.
  • At diagnosis, p21 methylation was not detected in any case of AML or ALL. p27 methylation occurred in 2 (4%) AML patients and in 1 (4%) ALL patient. p57 methylation occurred in 1 (2%) AML patient and in 1 (4%) ALL patient.
  • Therefore, methylation inactivation of the INK4/CDK/RB pathway in leukemia is infrequent.
  • [MeSH-major] Calcium-Binding Proteins / metabolism. Cell Cycle. Cyclin-Dependent Kinase Inhibitor Proteins / metabolism. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Alleles. Cell Line, Tumor. Humans. Polymerase Chain Reaction. Signal Transduction / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16315255.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CIB1 protein, human; 0 / Calcium-Binding Proteins; 0 / Cyclin-Dependent Kinase Inhibitor Proteins
  •  go-up   go-down


21. Gorschlüter M, Mey U, Strehl J, Schepke M, Lamberti C, Sauerbruch T, Glasmacher A: Cholecystitis in neutropenic patients: retrospective study and systematic review. Leuk Res; 2006 May;30(5):521-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We calculated a frequency of 0.4% among all neutropenic episodes in patients with acute leukemia or aggressive lymphoma undergoing myelosuppressive chemotherapy.
  • [MeSH-major] Cholecystitis / etiology. Leukemia / therapy. Lymphoma, Non-Hodgkin / therapy. Neutropenia / complications
  • [MeSH-minor] Acute Disease. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Cholecystitis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483649.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 41
  •  go-up   go-down


22. Mlombie Y: Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward. Malawi Med J; 2010 Jun;22(2):59-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia and aggressive lymphoma treatment in adults: it is time for Malawi to move forward.
  • [MeSH-major] Burkitt Lymphoma. Leukemia
  • [MeSH-minor] Acute Disease. Humans. Malawi. Practice Patterns, Physicians' / trends

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1975 Feb;19(2):201-8 [1240046.001]
  • [Cites] S Afr Med J. 2009 Apr;99(4):243-8 [19588777.001]
  • [CommentOn] Malawi Med J. 2009 Jun;21(2):86, 88-9 [20345012.001]
  • (PMID = 21618748.001).
  • [ISSN] 1995-7262
  • [Journal-full-title] Malawi medical journal : the journal of Medical Association of Malawi
  • [ISO-abbreviation] Malawi Med J
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Malawi
  • [Other-IDs] NLM/ PMC3345756
  •  go-up   go-down


23. Yue LJ, Chen XW, Li CR, Li CG, Shi HS, Zhang M: [Single-nucleotide polymorphisms of the cytidine deaminase gene in childhood with acute leukemia and normal Chinese children]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec;24(6):699-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Single-nucleotide polymorphisms of the cytidine deaminase gene in childhood with acute leukemia and normal Chinese children].
  • OBJECTIVE: Cytidine deaminase (CDA) is a key enzyme for metabolizing chemotherapeutic agent cytosine arabinoside (Ara-C), a deoxycytidine analog used for treatment of acute leukemia and lymphomas.
  • METHODS: The bone marrow samples from 87 childhood patients with acute leukemia and peripheral blood samples from 199 non-malignancy-bearing children were obtained to prepare complementary DNAs (cDNAs).
  • The distributive difference of each genotype was evaluated between children with acute leukemia and control children.
  • No association with susceptibility to disease was observed.
  • [MeSH-major] Cytidine Deaminase / genetics. Leukemia / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Acute Disease. Asian Continental Ancestry Group / genetics. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Male

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18067088.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


24. Liu Y, Tang SQ, Wang JW, Long H, Feng C, Zhang H: [Treatment of acute leukemia complicated by invasive aspergillosis in children]. Zhongguo Dang Dai Er Ke Za Zhi; 2009 Nov;11(11):901-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of acute leukemia complicated by invasive aspergillosis in children].
  • OBJECTIVE: To study the antifungal treatment and intensive chemotherapy in children with acute leukemia and invasive aspergillosis.
  • METHODS: The diagnosis and treatment of 4 cases of childhood acute leukemia complicated by invasive aspergillosis between July 2007 and July 2008 were studied retrospectively.
  • One child with proven aspergillosis and 3 with possible aspergillosis all had halo sign on CT at diagnosis.
  • CONCLUSIONS: The halo sign on CT may be a reliable indicator for the early diagnosis of invasive aspergillosis.
  • The preemptive antifungal therapy on the basis of the identification of a halo sign and the reversal of immunosuppression may improve the outcome of invasive aspergillosis.
  • [MeSH-major] Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Leukemia, Myeloid, Acute / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20113657.001).
  • [ISSN] 1008-8830
  • [Journal-full-title] Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
  • [ISO-abbreviation] Zhongguo Dang Dai Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antifungal Agents
  •  go-up   go-down


25. Gong H, Liu W, Zhou J, Xu H: Methylation of gene CHFR promoter in acute leukemia cells. J Huazhong Univ Sci Technolog Med Sci; 2005;25(3):240-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of gene CHFR promoter in acute leukemia cells.
  • In order to explore whether gene CHFR was inactivated by methylation in leukemia cells, the expression of CHFR was examined before and after treatment with demethylation agent in Molt-4, Jurkat and U937 leukemia cell lines by means of RT-PCR.
  • The methylation of promoter in Molt-4, Jurkat and U937 cells as well as 41 acute leukemia patients was analyzed by MS-PCR.
  • CHFR promoter methylation was detected in 39% of acute leukemia patients.
  • There was no difference in incidence of CHFR promoter methylation between acute myelocytic leukemia and acute lymphocytic leukemia.
  • In conclusion, CHFR is frequently inactivated in acute leukemia and is a good candidate for the leukemia supper gene.
  • By affecting mitotic checkpoint function, CHFR inactivation likely plays a key role in tumorigenesis in acute leukemia.
  • Moreover, the methylation of gene CHFR appears to be a good index with which to predict the sensitivity of acute leukemia to microtubule inhibitors.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA Methylation. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Drug Resist Updat. 2002 Dec;5(6):249-58 [12531181.001]
  • [Cites] Carcinogenesis. 2002 Oct;23(10):1695-9 [12376479.001]
  • [Cites] Nature. 2000 Jul 27;406(6794):430-5 [10935642.001]
  • [Cites] Oncogene. 2002 Apr 4;21(15):2328-33 [11948416.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):47-51 [12538348.001]
  • (PMID = 16201259.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  •  go-up   go-down


26. Figueroa ME, Melnick A, Greally JM: Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. Methods Mol Biol; 2009;538:395-407
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias.
  • The HELP assay allows methylation levels throughout the genome to be accurately determined so that the epigenetic state of leukemia cells can be identified, compared, and contrasted.
  • [MeSH-major] DNA / analysis. DNA Methylation. DNA-Cytosine Methylases / metabolism. Genome, Human. Leukemia / genetics. Polymerase Chain Reaction / methods
  • [MeSH-minor] Acute Disease. CpG Islands. Cytosine / chemistry. Humans. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277580.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 8J337D1HZY / Cytosine; 9007-49-2 / DNA; EC 2.1.1.- / DNA modification methylase HpaII; EC 2.1.1.- / DNA-Cytosine Methylases
  •  go-up   go-down


27. Ennis MK, Dingli D: Death by fusion for acute leukemia cells. Cancer Biol Ther; 2010 Mar 1;9(5):358-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Death by fusion for acute leukemia cells.
  • [MeSH-major] Leukemia / pathology

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Biol Ther. 2010 Mar 1;9(5):350-7 [20061812.001]
  • (PMID = 20104027.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comment; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


28. Köhler K, Regner A, Koenigsmann M, Franke A, Frommer J: [Illness perceptions of patients suffering from acute leukaemia one week after diagnosis]. Z Psychosom Med Psychother; 2005;51(4):388-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Illness perceptions of patients suffering from acute leukaemia one week after diagnosis].
  • OBJECTIVES: To investigate illness perceptions, treatment expectations, and treatment experiences of patients suffering from acute leukaemia in the initial stage of their disease.
  • METHODS: In the first week of treatment we interviewed twelve patients with acute leukaemia using a detailed semi-structured interview guide.
  • [MeSH-major] Leukemia, Myeloid, Acute / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Sick Role

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16402336.001).
  • [ISSN] 1438-3608
  • [Journal-full-title] Zeitschrift für Psychosomatische Medizin und Psychotherapie
  • [ISO-abbreviation] Z Psychosom Med Psychother
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


29. Owen C, Fitzgibbon J, Paschka P: The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol; 2010 Mar;28(1):13-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia.
  • Recurrent genetic aberrations are important predictors of outcome in acute myeloid leukaemia (AML).
  • WT1 mutations occur in approximately 10% of adult AML patients at diagnosis and are most frequent in the cytogenetically normal (CN) AML subgroup.
  • [MeSH-major] Genes, Wilms Tumor. Leukemia, Myeloid, Acute / genetics. Mutation / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013787.001).
  • [ISSN] 1099-1069
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0700052; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / WT1 Proteins
  • [Number-of-references] 75
  •  go-up   go-down


30. Shadduck RK, Latsko JM, Rossetti JM, Haq B, Abdulhaq H: Recent advances in myelodysplastic syndromes. Exp Hematol; 2007 Apr;35(4 Suppl 1):137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal bone marrow disorders characterized by both bone marrow failure and a propensity for development of acute myeloid leukemia.
  • While the majority of patients are diagnosed with low-grade disease, approximately two-thirds will succumb to complications of peripheral blood cytopenias or progression to acute leukemia.
  • Subsequent work with the thalidomide derivative lenalidomide resulted in marked erythroid and cytogenetic responses in individuals with the 5q- abnormality.
  • [MeSH-minor] Antimetabolites, Antineoplastic / therapeutic use. Chromosome Aberrations. Chromosomes, Human, Pair 5 / genetics. Clinical Trials as Topic. DNA Methylation / drug effects. Enzyme Inhibitors / therapeutic use. Humans. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Leukemia, Myeloid, Acute / physiopathology. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology


31. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A: The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica; 2006 Aug;91(8):1068-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The cohort was formed of 11,802 patients with hematologic malignacies: acute leukemia (myeloid 3012, lymphoid 1173), chronic leukemia (myeloid 596, lymphoid 1104), lymphoma (Hodgkin's 844, non-Hodgkin's 3457), or multiple myeloma (1616).
  • There were 538 proven or probable IFI (4.6%); 373 (69%) occurred in patients with acute myeloid leukemia.
  • INTERPRETATION AND CONCLUSIONS: Patients with hematologic malignancies are currently at higher risk of IFI caused by molds than by yeasts, and the incidence of IFI is highest among patients with acute myeloid leukemia.

  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885047.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


32. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, Ferrell RE: Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet; 2006 Apr;119(3):276-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytidine deaminase (CDA) hydrolytically deaminates and irreversibly deactivates the chemotherapeutic agent cytosine arabinoside (Ara-C), a deoxycytidine analog used for treatment of acute leukemias and lymphomas.
  • As predicted from the in vitro analysis, individuals homozygous for common haplotype (ACC/ACC) showed higher levels of CDA enzymatic activity as individuals heterozygous for the wild type and low expressing haplotype (ACC/ATC).

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):231-7 [2438776.001]
  • [Cites] Cancer Res. 1979 Mar;39(3):1102-7 [427752.001]
  • [Cites] Nat New Biol. 1971 Sep 22;233(38):109-10 [5285962.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5401-7 [7923172.001]
  • [Cites] Exp Hematol. 1998 May;26(5):421-5 [9590659.001]
  • [Cites] Pharmacogenomics J. 2004;4(5):307-14 [15224082.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):257-61 [3035720.001]
  • [Cites] Eur J Cancer. 1976 Jul;12(7):567-73 [1066282.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Sep;85(18):6851-5 [3137573.001]
  • [Cites] Hum Gene Ther. 1990 Spring;1(1):31-41 [2081183.001]
  • [Cites] J Mol Biol. 1994 Jan 14;235(2):635-56 [8289286.001]
  • [Cites] Clin Pharmacol Ther. 1971 Nov-Dec;12(6):944-54 [5289712.001]
  • [Cites] Br J Haematol. 1998 Dec;103(4):1096-103 [9886326.001]
  • [Cites] Pharmacogenetics. 2003 Jan;13(1):29-38 [12544510.001]
  • [Cites] Blood. 1998 Jun 1;91(11):4127-35 [9596658.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(3):173-7 [1733548.001]
  • [Cites] Br J Haematol. 1974 May;27(1):39-46 [4368900.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 17;206(2):486-91 [7826366.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Jan 15;190(1):1-7 [8422236.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2620-4 [15814642.001]
  • [Cites] Blood. 1997 Sep 1;90(5):1968-76 [9292531.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1919-24 [8946931.001]
  • [Cites] Exp Hematol. 1996 Sep;24(11):1340-6 [8862446.001]
  • [Cites] Br J Haematol. 2000 Aug;110(2):285-91 [10971383.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):728-35 [14744791.001]
  • [Cites] Arch Biochem Biophys. 1991 Nov 1;290(2):285-92 [1929398.001]
  • [Cites] Protein Expr Purif. 1996 Sep;8(2):247-53 [8812871.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 22;1443(3):323-33 [9878810.001]
  • [Cites] Leukemia. 2001 Jun;15(6):875-90 [11417472.001]
  • [Cites] Biochim Biophys Acta. 1996 Jun 13;1312(2):99-104 [8672545.001]
  • [Cites] Cancer Gene Ther. 1996 Sep-Oct;3(5):331-8 [8894252.001]
  • (PMID = 16446974.001).
  • [ISSN] 0340-6717
  • [Journal-full-title] Human genetics
  • [ISO-abbreviation] Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


33. De Braekeleer M, Morel F, Le Bris MJ, Herry A, Douet-Guilbert N: The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res; 2005 May-Jun;25(3B):1931-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia.
  • The cloning of the genes located at the breakpoints of chromosomal translocations in leukemia and lymphoma has led to the identification of new genes involved in carcinogenesis.
  • Molecular studies of the breakpoint of several translocations involving chromosomal band 11q23 led to the cloning of a gene that was named MLL.
  • Based on 7969 cases of acute myeloblastic leukemia (AML) and 1252 cases of acute lymphoblastic leukemia (ALL) taken from the literature, band 11q23 and/or the MLL gene was involved in 5.2% of AML and 22% of ALL.
  • Differences in the frequency and the distribution of translocations were noted according to the type of acute leukemia and age of the patients.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Chromosome Banding. Histone-Lysine N-Methyltransferase. Humans. Myeloid-Lymphoid Leukemia Protein. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158928.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 55
  •  go-up   go-down


34. Chiaretti S, Messina M, Tavolaro S, Zardo G, Elia L, Vitale A, Fatica A, Gorello P, Piciocchi A, Scappucci G, Bozzoni I, Fozza C, Candoni A, Guarini A, Foà R: Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223. Haematologica; 2010 Jul;95(7):1114-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling identifies a subset of adult T-cell acute lymphoblastic leukemia with myeloid-like gene features and over-expression of miR-223.
  • BACKGROUND: Until recently, few molecular aberrations were recognized in acute lymphoblastic leukemia of T-cell origin; novel lesions have recently been identified and a certain degree of overlap between acute myeloid leukemia and T-cell acute lymphoblastic leukemia has been suggested.
  • To identify novel T-cell acute lymphoblastic leukemia entities, gene expression profiling was performed and clinico-biological features were studied.
  • DESIGN AND METHODS: Sixty-nine untreated adults with T-cell acute lymphoblastic leukemia were evaluated by oligonucleotide arrays: unsupervised and supervised analyses were performed.
  • Of these, one branch included seven patients whose gene expression profile resembled that of acute myeloid leukemia.
  • These cases were characterized by over-expression of a large set of myeloid-related genes for surface antigens, transcription factors and granule proteins.
  • We, therefore, evaluated the expression levels of miR-223, involved in myeloid differentiation: these cases had significantly higher levels of miR-223 than had the other cases of T-cell acute lymphoblastic leukemia, with values comparable to those observed in acute myeloid leukemia.
  • CONCLUSIONS: Using gene profiling we identified a subset of adult T-cell acute lymphoblastic leukemia, accounting for 10% of the cases analyzed, which displays myeloid features.
  • These cases were not recognized by standard approaches, underlining the importance of gene profiling in identifying novel acute leukemia subsets.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. MicroRNAs / genetics


35. Rollison DE, Helzlsouer KJ, Pinney SM: Personal hair dye use and cancer: a systematic literature review and evaluation of exposure assessment in studies published since 1992. J Toxicol Environ Health B Crit Rev; 2006 Sep-Oct;9(5):413-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hair dyes are widely used, and permanent hair dye is the most commonly used type of product.
  • Quality of exposure assessment was rated between 1+ (lowest quality: assessed ever use of hair dyes) and 4+ (highest quality: assessed dye type [permanent/nonpermanent], dye color/shade, frequency and duration of use).
  • Associations between personal hair dye use and non-Hodgkin's lymphoma, multiple myeloma, acute leukemia, and bladder cancer were observed in at least one well-designed study with detailed exposure assessment (rated 3+ or 4+), but were not consistently observed across studies.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17492526.001).
  • [ISSN] 1521-6950
  • [Journal-full-title] Journal of toxicology and environmental health. Part B, Critical reviews
  • [ISO-abbreviation] J Toxicol Environ Health B Crit Rev
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES006096
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hair Dyes
  • [Number-of-references] 40
  •  go-up   go-down


36. Othman S: Thyroiditis mimicking relapse of acute lymphoblastic leukemia: Gallium-67 scan suggested the diagnosis. Indian J Med Paediatr Oncol; 2010 Jul;31(3):94-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroiditis mimicking relapse of acute lymphoblastic leukemia: Gallium-67 scan suggested the diagnosis.
  • Acute lymphoblastic leukemia (ALL) is the most common form of leukemia in childhood and accounts for 85% of cases.
  • Thyroid disease has been reported to have a strong association with acute leukemia.
  • We report a case of a 13-year-old female patient who presented with fever and suspected disease relapse after a period of disease remission; however, gallium-67 citrate whole body scan suggested the diagnosis of thyroiditis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Sep;17(9):1912-4 [12970797.001]
  • [Cites] Am J Hematol. 1992 Feb;39(2):102-7 [1550101.001]
  • [Cites] Am J Hematol. 1997 Aug;55(4):212-5 [9257883.001]
  • [Cites] Clin Nucl Med. 1994 May;19(5):413-5 [8039315.001]
  • [Cites] J Nucl Med. 1998 Nov;39(11):1983-6 [9829594.001]
  • [Cites] South Med J. 1989 May;82(5):647-9 [2717991.001]
  • (PMID = 21206717.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3009443
  • [Keywords] NOTNLM ; Acute lymphoblastic leukemia / gallium-67 scan / thyroiditis
  •  go-up   go-down


37. Bies J, Sramko M, Fares J, Rosu-Myles M, Zhang S, Koller R, Wolff L: Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood; 2010 Aug 12;116(6):979-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia.
  • Inactivation of p15INK4b, an inhibitor of cyclin-dependent kinases, through DNA methylation is one of the most common epigenetic abnormalities in myeloid leukemia.
  • Although this suggests a key role for this protein in myeloid disease suppression, experimental evidence to support this has not been reported.
  • To address whether this event is critical for premalignant myeloid disorders and leukemia development, mice were generated that have loss of p15Ink4b specifically in myeloid cells.
  • The p15Ink4b(fl/fl)-LysMcre mice develop nonreactive monocytosis in the peripheral blood accompanied by increased numbers of myeloid and monocytic cells in the bone marrow resembling the myeloproliferative form of chronic myelomonocytic leukemia.
  • Spontaneous progression from chronic disease to acute leukemia was not observed.
  • Nevertheless, MOL4070LTR retrovirus integrations provided cooperative genetic mutations resulting in a high frequency of myeloid leukemia in knockout mice.
  • Two common retrovirus insertion sites near c-myb and Sox4 genes were identified, and their transcript up-regulated in leukemia, suggesting a collaborative role of their protein products with p15Ink4b-deficiency in promoting malignant disease.
  • This new animal model demonstrates experimentally that p15Ink4b is a tumor suppressor for myeloid leukemia, and its loss may play an active role in the establishment of preleukemic conditions.


38. Coiteux V, Onclercq-Delic R, Fenaux P, Amor-Guéret M: Predisposition to therapy-related acute leukemia with balanced chromosomal translocations does not result from a major constitutive defect in DNA double-strand break end joining. Leuk Res; 2007 Mar;31(3):353-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predisposition to therapy-related acute leukemia with balanced chromosomal translocations does not result from a major constitutive defect in DNA double-strand break end joining.
  • The frequency of acute myeloid leukemia (AML) with balanced chromosomal translocations arising after anticancer therapy with DNA-damaging agents such as DNA topoisomerase II inhibitors has increased over the last two decades.
  • It has been reported that DNA double-strand break (DSB) repair by the non-homologous end-joining (NHEJ) pathway is impaired in myeloid leukemia cells.
  • We show here that DSB repair is accurate, in vivo, in non-tumoral cells derived from patients who developed t-AML with t(9;11) or t(15;17) translocation after treatment for a first cancer with DNA topoisomerase II inhibitors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. DNA Breaks, Double-Stranded / drug effects. DNA Repair. DNA Topoisomerases, Type II. Leukemia, Myeloid / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Line, Tumor. Chromosomes, Human, Pair 11 / genetics. Chromosomes, Human, Pair 15 / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 9 / genetics. Enzyme Inhibitors / pharmacology. Female. Humans. Male. Middle Aged. Structure-Activity Relationship. Topoisomerase II Inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890283.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Topoisomerase II Inhibitors; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


39. Abdelhaleem M, Shago M, Sayeh E, Abla O: Childhood myeloid/natural killer precursor acute leukemia with novel chromosomal aberrations der(5)t(4;5)(q31;q31.3) and t(14;17)(q32;q23). Cancer Genet Cytogenet; 2007 Oct 15;178(2):141-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood myeloid/natural killer precursor acute leukemia with novel chromosomal aberrations der(5)t(4;5)(q31;q31.3) and t(14;17)(q32;q23).
  • We report a unique case of childhood acute leukemia.
  • The leukemia blasts had lymphoblastoid appearance and expressed CD33, CD13, CD34, CD4, CD7, and CD56.
  • The morphology and immunophenotype were most consistent with myeloid/natural killer precursor acute leukemia.
  • The blasts had a complex karyotype, including two chromosomal aberrations, der(5)t(4;5)(q31;q31.3) and t(14;17)(q32;q23), not previously described in childhood acute leukemia.
  • The patient achieved morphological remission following myeloid-based leukemia therapy.
  • [MeSH-major] Chromosomes, Human, Pair 4. Chromosomes, Human, Pair 5. Leukemia, Promyelocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / pathology


40. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, Faderl S, Thomas D, Wierda W, Kornblau S, Ferrajoli A, Albitar M, McKeegan E, Grimm DR, Mueller T, Holley-Shanks RR, Sahelijo L, Gordon GB, Kantarjian HM, Giles FJ: Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res; 2005 Sep 15;11(18):6615-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias.
  • One patient with relapsed acute myelogenous leukemia achieved a complete remission that was sustained for 2 months.
  • Four other patients had transient hematologic improvements, consisting of a decrease in peripheral blood blasts and improvements in platelet counts.
  • CONCLUSION: Further assessment of ABT-751, especially in combination with other agents, in patients with acute leukemias is warranted.
  • [MeSH-minor] Acute Disease. Adult. Aged. Antigens, CD / analysis. Antigens, CD146. Antigens, CD31 / analysis. Antigens, CD45 / analysis. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Constipation / chemically induced. Diarrhea / chemically induced. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Endothelial Cells / chemistry. Female. Glycoproteins / analysis. Humans. Leukemia / blood. Leukemia / drug therapy. Leukemia / genetics. Male. Microtubules / metabolism. Middle Aged. Mutation. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / drug therapy. Myelodysplastic Syndromes / genetics. Nausea / chemically induced. Neoplasm Recurrence, Local. Neoplastic Cells, Circulating / chemistry. Neural Cell Adhesion Molecules / analysis. Peptides / analysis. Treatment Outcome. Tubulin / genetics. Vomiting / chemically induced

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166440.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT751; 0 / AC133 antigen; 0 / Antigens, CD; 0 / Antigens, CD146; 0 / Antigens, CD31; 0 / Antineoplastic Agents; 0 / Glycoproteins; 0 / Neural Cell Adhesion Molecules; 0 / Peptides; 0 / Sulfonamides; 0 / Tubulin; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


41. Tsimberidou AM, Keating MJ: Richter syndrome: biology, incidence, and therapeutic strategies. Cancer; 2005 Jan 15;103(2):216-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Richter's transformation denotes the development of high-grade non-Hodgkin lymphoma, prolymphocytic leukemia, Hodgkin disease, or acute leukemia in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.
  • Multiple genetic defects, such as mutations of the p53 tumor suppressor gene, p16INK4A, and p21, loss of p27 expression, deletion of retinoblastoma, increased copy number of C-MYC, and decreased expression of the A-MYB gene, have been described.
  • Therapeutic strategies include intensive chemotherapy, monoclonal antibodies, and stem cell transplantation.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Assessment. Severity of Illness Index. Stem Cell Transplantation / methods. Survival Analysis. Syndrome. Treatment Outcome

  • Genetic Alliance. consumer health - Richter syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15578683.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 159
  •  go-up   go-down


42. Kim H, Noh EK, Lee EJ, Baek JH, Shin SJ, Park JH, Lee KH, Min YJ: Enhanced bactericidal function by WKYMVm in patients with acute leukemia. Leuk Res; 2008 May;32(5):717-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced bactericidal function by WKYMVm in patients with acute leukemia.
  • To extend these observations, we evaluated whether WKYMVm can enhance leukocyte bactericidal activity in patients with acute leukemia (AL).
  • During induction chemotherapy, there were significant increases in bactericidal activity in the presence and absence of 1nM WKYMVm, with higher bactericidal activities at the time of complete remission than at the time of diagnosis or on day 15.
  • TNF alpha, IL-1b and IL-6 showed significant negative correlations with bactericidal activities of patient neutrophils at time of diagnosis, and IL-4 showed a significant positive correlation with bactericidal activities.
  • [MeSH-major] Blood Bactericidal Activity. Leukemia, Myeloid, Acute / immunology. Oligopeptides / physiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17950844.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Oligopeptides; 0 / Trp-Lys-Tyr-Met-Val-Met
  •  go-up   go-down


43. Feng M, Li YC: [Expression of erythropoietin receptor in leukemia cells and relation of erythropoietin level with leukemic anemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec;16(6):1265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of erythropoietin receptor in leukemia cells and relation of erythropoietin level with leukemic anemia].
  • This study was purposed to investigate the expression of erythropoietin receptor (EPOR) in leukemic cells and the relationship of serum erythropoietin level with anemia in acute leukemia patients, so as to provide a new theoretical basis for the cytokine therapy in acute leukemia with anemia.
  • The mechanism of negative feedback to anemia in acute leukemia is intact.
  • Anemia of acute leukemia is not completely associated with inadequate erythropoietin production and relates to hemopoiesis defect that considered as the main reason.
  • Recombinant human erythropoietin is widely used in treatment of anemia caused by acute leukemia.
  • Whether the treatment with rh-EPO for acute leukemia with anemia will enhance the proliferation of leukemia cells, this problem should be explored further.

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099624.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptors, Erythropoietin; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


44. Crawford MW, Pehora C, Lopez AV: Drug-induced acute pancreatitis in children receiving chemotherapy for acute leukemia: does propofol increase the risk? Anesth Analg; 2009 Aug;109(2):379-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced acute pancreatitis in children receiving chemotherapy for acute leukemia: does propofol increase the risk?
  • BACKGROUND: The use of propofol is controversial in patients with a history of acute pancreatitis or those taking drugs, including certain chemotherapeutic drugs, that are associated with pancreatitis.
  • METHODS: To investigate this issue, we reviewed the medical records of all children who were diagnosed with pancreatitis while receiving chemotherapy for acute leukemia during a 5-year period.
  • RESULTS: A temporal relationship between propofol use and development of acute pancreatitis could not be established.
  • CONCLUSION: Propofol can be considered for general anesthesia in children who are receiving chemotherapeutic drugs that are themselves associated with acute pancreatitis or those who have a history of chemotherapy-induced pancreatitis.
  • [MeSH-major] Anesthetics, Intravenous / adverse effects. Antineoplastic Agents / adverse effects. Leukemia / complications. Pancreatitis / chemically induced. Pancreatitis / epidemiology. Propofol / adverse effects
  • [MeSH-minor] Acute Disease. Adolescent. Anesthesia, General / adverse effects. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Humans. Intraoperative Complications / epidemiology. Male. Risk Assessment

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • Hazardous Substances Data Bank. PROPOFOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19608806.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Intravenous; 0 / Antineoplastic Agents; YI7VU623SF / Propofol
  •  go-up   go-down


45. Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV: Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer; 2006 Oct 15;107(8):1743-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For patients with acute leukemia or those who undergo bone marrow transplantation, prophylaxis with fluoroquinolones diminished the risk of death from any cause by 33% (95% confidence interval [95% CI], 2-54%).
  • Thus, 55 patients who have acute leukemia or who undergo bone marrow transplantation must receive prophylaxis to prevent 1 death.
  • Patients who are treated for acute leukemia should be offered prophylaxis with ciprofloxacin or levofloxacin.
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / adverse effects. Bone Marrow Transplantation. Ciprofloxacin / therapeutic use. Decision Making. Drug Resistance. Enterocolitis, Pseudomembranous / epidemiology. Enterocolitis, Pseudomembranous / prevention & control. Gram-Positive Bacterial Infections / epidemiology. Gram-Positive Bacterial Infections / prevention & control. Humans. Leukemia / drug therapy. Levofloxacin. Lymphoma / drug therapy. Neoplasms / drug therapy. Ofloxacin / therapeutic use

  • Hazardous Substances Data Bank. Levofloxacin .
  • Hazardous Substances Data Bank. Ofloxacin .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16977651.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5E8K9I0O4U / Ciprofloxacin; 6GNT3Y5LMF / Levofloxacin; A4P49JAZ9H / Ofloxacin
  • [Number-of-references] 46
  •  go-up   go-down


46. Park HH, Kim M, Lee BH, Lim J, Kim Y, Lee EJ, Min WS, Kang CS, Kim WI, Shim SI, Han K: Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia. Ann Clin Lab Sci; 2006;36(1):7-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia.
  • The quantitative levels of intracellular cytokines IL-4, IL-10, and IFN-gamma (ie, the number of bound PE-conjugated antibody molecules/cell) of leukemic cells and bone marrow T cells (bmT cells) of acute leukemia patients were analyzed by flow cytometry.
  • The leukemic cell IL-4 level was highest in the monocytic AML group (1735 +/- 1056) and lowest in the dysplastic AML group (960 +/- 545).
  • The IFN-gamma level was highest in the acute promyelocytic leukemia (APL) group (495 +/- 159), and lowest in the ALL group (252 +/- 119).
  • The IL-10 level was not significantly different among the diagnosis groups.
  • The leukemic cell cytokine levels were lowest and bmT cell cytokine levels were highest in the dysplastic AML group.
  • The cytokine levels of bmT cells at the time of CR became normal and were not different among the diagnosis groups.
  • In summary, leukemic cell and bmT cell cytoplasmic expression profiles of IL-4, IL-10, and IFN-gamma are characteristic for each diagnostic group of acute leukemia patients and the profiles of bmT cells are normal at the time of CR.
  • [MeSH-major] Bone Marrow Cells / metabolism. Interferon-gamma / blood. Interleukin-10 / blood. Interleukin-4 / blood. Leukemia / metabolism. T-Lymphocytes / metabolism
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / drug therapy. Leukemia, Myeloid / metabolism. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Remission Induction

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501231.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


47. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, Newman DJ, Byrd JC, Kinghorn AD, Grever MR: The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood; 2009 May 7;113(19):4656-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.
  • Therapeutic options for advanced B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are limited.
  • In the National Cancer Institute cell line screen, the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in leukemia and selectivity for B cells.
  • We investigated silvestrol efficacy using primary human B-leukemia cells, established B-leukemia cell lines, and animal models.
  • At this concentration, there is no difference in sensitivity of cells from patients with or without the del(17p13.1) abnormality.
  • In vivo, silvestrol causes significant B-cell reduction in Emu-Tcl-1 transgenic mice and significantly extends survival of 697 xenograft severe combined immunodeficient (SCID) mice without discernible toxicity.
  • These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Oct;17(10):1981-9 [14513048.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6955-60 [12011454.001]
  • [Cites] J Org Chem. 2004 May 14;69(10):3350-8 [15132542.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1177-84 [12149195.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44791-800 [12237314.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1466-71 [12697868.001]
  • [Cites] Blood. 2003 Jul 15;102(2):652-8 [12649137.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):367-74 [12663328.001]
  • [Cites] Arch Biochem Biophys. 2003 Sep 15;417(2):141-52 [12941295.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Jun;50(3):223-61 [15182827.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):26915-21 [15078892.001]
  • [Cites] Leukemia. 2004 Jul;18(7):1207-14 [15116122.001]
  • [Cites] Anticancer Res. 1988 May-Jun;8(3):355-67 [3389740.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 5;83(11):757-66 [2041050.001]
  • [Cites] J Cell Physiol. 1996 Mar;166(3):523-36 [8600156.001]
  • [Cites] Antiviral Res. 1995 Nov;28(3):265-79 [8629818.001]
  • [Cites] J Nat Prod. 1997 Jun;60(6):606-8 [9214732.001]
  • [Cites] Z Naturforsch C. 1999 Jan-Feb;54(1-2):55-60 [10223787.001]
  • [Cites] J Immunol Methods. 2004 Nov;294(1-2):15-22 [15604012.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1259-62 [15467463.001]
  • [Cites] Immunology. 2005 Apr;114(4):441-9 [15804279.001]
  • [Cites] J Immunol. 2005 Jun 1;174(11):7075-84 [15905551.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2513-9 [15972445.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2):240-9 [16616071.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3978-80 [16618714.001]
  • [Cites] Cell Death Differ. 2006 Aug;13(8):1419-21 [16645636.001]
  • [Cites] Anticancer Agents Med Chem. 2006 Jul;6(4):319-45 [16842234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11713-8 [16864779.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1334-8 [16670263.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3349-56 [17094452.001]
  • [Cites] Blood. 2007 Jan 15;109(2):399-404 [17003373.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2008-13 [17068155.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):799-804 [17283363.001]
  • [Cites] Expert Opin Emerg Drugs. 2007 Mar;12(1):165-79 [17355221.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2144-50 [17404098.001]
  • [Cites] J Biol Chem. 2007 Aug 3;282(31):22551-62 [17553788.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2175-83 [17695501.001]
  • [Cites] Cell Death Differ. 2007 Sep;14(9):1576-82 [17612585.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1839-46 [17565740.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(41):7831-4 [17806093.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(41):7835-8 [17823902.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3190-9 [18192508.001]
  • [Cites] J Clin Invest. 2008 Jul;118(7):2651-60 [18551192.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3807-17 [18599795.001]
  • [Cites] J Am Chem Soc. 2009 Feb 4;131(4):1607-16 [19140688.001]
  • [Cites] Z Naturforsch C. 1999 Dec;54(12):1075-83 [10685499.001]
  • [Cites] Blood. 2000 Jul 15;96(2):393-7 [10887097.001]
  • [Cites] Biotechniques. 2001 Sep;31(3):464, 466 [11570486.001]
  • [Cites] EMBO J. 2001 Dec 3;20(23):6627-36 [11726499.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1885-93 [11877256.001]
  • [Cites] Leukemia. 2002 Apr;16(4):444-54 [11960321.001]
  • [Cites] Blood. 2004 May 1;103(9):3278-81 [14726385.001]
  • (PMID = 19190247.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U19 CA052956; United States / NCI NIH HHS / CA / P01CA125066; United States / NCI NIH HHS / CA / P01 CA125066; United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / CA52956
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Reactive Oxygen Species; 0 / Tcl1 protein, mouse; 0 / Triterpenes; 0 / silvestrol
  • [Other-IDs] NLM/ PMC2680369
  •  go-up   go-down


48. Mrózek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, Watson MS, Arthur DC, Tantravahi R, Heerema NA, Koduru PR, Block AW, Qumsiyeh MB, Edwards CG, Sterling LJ, Holland KB, Bloomfield CD: Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol; 2008 Aug;33(2):239-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience.
  • The Cancer and Leukemia Group B has performed central review of karyotypes submitted by institutional cytogenetics laboratories from patients with acute myeloid (AML) and acute lymphoblastic (ALL) leukemia since 1986.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2002 Dec 15;100(13):4372-80 [12393388.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1521-8 [12886238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1030-5 [16418266.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):790-7 [16418499.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1791-9 [16254134.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 2):3564s-71s [16740786.001]
  • [Cites] Blood. 2006 Jul 1;108(1):63-73 [16522815.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3904-11 [16921041.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1677-83 [16670265.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):450-74 [17054678.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3280-8 [16840728.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3898-905 [16912223.001]
  • [Cites] Blood. 2007 Jan 15;109(2):431-48 [16960150.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1198-203 [17410184.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jun;13(6):655-64 [17531775.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3337-43 [17577018.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1308-16 [17485549.001]
  • [Cites] Am J Hematol. 2007 Dec;82(12):1056-62 [17696203.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1552-9 [17940205.001]
  • [Cites] Am J Clin Pathol. 2008 Mar;129(3):478-85 [18285273.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Semin Oncol. 2008 Aug;35(4):365-77 [18692687.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4595-602 [18559874.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):624-33 [14726504.001]
  • [Cites] Blood Rev. 2004 Jun;18(2):115-36 [15010150.001]
  • [Cites] Haematologica. 2004 Apr;89(4):408-18 [15075074.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2410-8 [15197203.001]
  • [Cites] Haematologica. 2004 Sep;89(9):1072-81 [15377468.001]
  • [Cites] Ann Med. 2004;36(7):492-503 [15513300.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4290-301 [15514371.001]
  • [Cites] Arch Pathol Lab Med. 1988 Nov;112(11):1085-90 [3178421.001]
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):776-9 [8343040.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3983-93 [10339508.001]
  • [Cites] Blood. 2005 May 1;105(9):3434-41 [15650057.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Oct 15;114(2):108-11 [10549265.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Cytogenet Cell Genet. 2000;91(1-4):124-7 [11173843.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2482-92 [11331327.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):19-47 [11355922.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7233-9 [11585760.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1041-51 [12370753.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1224-8 [15902281.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3740-6 [16051734.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3733-9 [16076867.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • (PMID = 18636143.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA047577; United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / U10 CA101140-06; United States / NCI NIH HHS / CA / CA016058-34; United States / NCI NIH HHS / CA / CA16058; United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / U10 CA077658; United States / NCI NIH HHS / CA / CA02599; United States / NCI NIH HHS / CA / U10 CA032291-27; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / P30 CA016058-34; United States / NCI NIH HHS / CA / U10 CA016450-28; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / U10 CA077658-12; United States / NCI NIH HHS / CA / U10 CA035279; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA047642-19; United States / NCI NIH HHS / CA / U10 CA031946-28; United States / NCI NIH HHS / CA / CA35279; United States / NCI NIH HHS / CA / CA032291-27; United States / NCI NIH HHS / CA / CA077658-12; United States / NCI NIH HHS / CA / U10 CA077440; United States / NCI NIH HHS / CA / CA16450; United States / NCI NIH HHS / CA / CA031946-28; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / CA77440; United States / NCI NIH HHS / CA / CA047642-19; United States / NCI NIH HHS / CA / U10 CA047559; United States / NCI NIH HHS / CA / P30 CA016058; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA77658; United States / NCI NIH HHS / CA / CA016450-28; United States / NCI NIH HHS / CA / U10 CA047642; United States / NCI NIH HHS / CA / U10 CA047577-22; United States / NCI NIH HHS / CA / CA101140-06; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA047577-22; United States / NCI NIH HHS / CA / CA47545
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Other-IDs] NLM/ NIHMS119024; NLM/ PMC3607284
  •  go-up   go-down


49. Dimou J, Jithoo R, Tsui A, Morokoff AP: Spinal cord compression as the initial presentation of acute biphenotypic leukaemia. J Clin Neurosci; 2009 Dec;16(12):1696-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression as the initial presentation of acute biphenotypic leukaemia.
  • Acute biphenotypic leukaemia (BAL) is an uncommon haematological malignancy with features of myeloid and lymphoid origin and poor overall prognosis.
  • Histopathology confirmed the diagnosis of acute biphenotypic (B/myeloid) leukaemia.
  • He succumbed to the disease three months post-diagnosis after failing induction chemotherapy.
  • While central nervous system involvement with acute leukaemia is well recognised, this is the first reported patient with spinal cord compression secondary to this leukaemia subtype.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / etiology. Spinal Cord Compression / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815414.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antigens, CD79; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


50. Yamamoto S, Toyama D, Yatsuki H, Higashimoto K, Soejima H, Isoyama K: Acute megakaryocytic leukemia (AMKL,FAB;M7) with Beckwith-Wiedemann syndrome. Pediatr Blood Cancer; 2010 Oct;55(4):733-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute megakaryocytic leukemia (AMKL,FAB;M7) with Beckwith-Wiedemann syndrome.
  • Although patients with BWS are known to have a higher incidence of embryonal tumors, there has been no reports associated with acute leukemia.
  • This report describes the case of a patient with BWS who developed Acute Megakaryocytic Leukemia (AMKL,FAB;M7).
  • This patient exhibited no therapy-related toxicity after chemotherapy, suggesting that acute leukemia with BWS may not require a reduction in dosage.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / complications. Leukemia, Megakaryoblastic, Acute / etiology

  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • (PMID = 20589645.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, Ramganesh S, Richardson R, Mehta S, Lapinsky SE: Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother; 2009 Sep;43(9):1419-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, RCA has been associated with significant metabolic complications including hypocalcemia, hypernatremia, metabolic alkalosis, and citrate toxicity.
  • OBJECTIVE: To describe our experience with a newly implemented RCA protocol with acid citrate dextrose formula A (ACD-A) and intravenous calcium gluconate, for use with PrismaFlex CRRT in critically ill patients with acute kidney injury.
  • Six patients, 3 with acute leukemia, required transfusion of 2 or more units of packed red blood cells in 24 hours.
  • [MeSH-major] Acute Kidney Injury / therapy. Anticoagulants / administration & dosage. Citric Acid / administration & dosage. Glucose / analogs & derivatives. Renal Replacement Therapy / methods

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. CITRIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19690224.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 13838-07-8 / acid citrate dextrose; 2968PHW8QP / Citric Acid; IY9XDZ35W2 / Glucose; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


52. Wu LP, Chen FX, Lu HM, Wu ZL, Wu ZL: [Biological characteristics of bone marrow-derived mesenchymal stem cells in children with acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):734-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biological characteristics of bone marrow-derived mesenchymal stem cells in children with acute leukemia].
  • This study was aimed to investigate the conditions of culturing in vitro mesenchymal stem cells (MSCs) derived from bone marrow of children with acute leukemia and the biological characteristics of MSCs from leukemia children.
  • The bone marrow MSCs of acute leukemia children were isolated by density gradient centrifugation combined with adherent segregating method and cultured in DMEM/F12.
  • The morphology of Wright stained MSCs was observed under inverted microscope.
  • Cell surface markers were analyzed with flow cytometry.
  • The results indicated that BM-MSCs of acute leukemia children could be successfully cultured in vitro in appropriate conditions.
  • The MSCs from leukemia children could be induced into adipocytes and osteocytes in appropriate conditions.
  • It is concluded that (1) MSCs derived from children with acute leukemia can be successfully cultured and passaged in vitro;.
  • (2) MSCs from leukemia children not received chemotherapy are more successfully cultured in vitro than those received chemotherapy;.
  • (3) the common biological characteristics of MSCs from children with acute leukemia are same as the MSCs from healthy person.


53. Abdulsalam AH: Chemotherapeutic trial for acute leukemia in Iraq. Turk J Haematol; 2009 Dec 5;26(4):216
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapeutic trial for acute leukemia in Iraq.
  • [Transliterated title] Irak'ta akut lösemi için kemoterapötik deneme.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265640.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


54. Iguchi T, Yamada Y, Awaya N, Ikeda Y, Okamoto S, Kizaki M: Multilineage involvement of light microscopic myeloperoxidase-negative acute leukemia. Int J Hematol; 2005 Nov;82(4):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilineage involvement of light microscopic myeloperoxidase-negative acute leukemia.
  • The classification of acute leukemia has traditionally been based on a combination of morphology and cytochemical staining data, including myeloperoxidase (MPO) reaction; however, a recent World Health Organization (WHO) classification entails use of cytogenetic and molecular findings in addition to the classic morphological and immunophenotypic analyses.
  • These cases may be classified as acute leukemia of ambiguous lineage in the recent WHO classification.
  • We report the case of a 49-year-old man with acute leukemia with multilineage phenotypes.
  • Morphological findings led to a diagnosis of acute myeloid leukemia M2 by the French-American-British classification, but at light microscopy the results of MPO staining were negative for blast cells.
  • In contrast, results of reverse transcription polymerase chain reaction and fluorescence-activated cell sorter analyses were positive for expression of MPO messenger RNA and protein.
  • The blast cells expressed CD4, CD19, CD22, CD33, CD38, CD79a, and HLA-DR and showed rearrangement of the immunoglobulin heavy chain and TCR-3 genes.
  • Results of immunoelectron microscopic analysis of the blast cells were positive for MPO, CD19, CD33, CD34, CD38 and glycophorin A but not for platelet peroxidase.
  • According to these results, the blast cells had at least 4 lineage phenotypes.
  • We concluded that the multiparameter analyses conducted in this case, including immunological and ultrastructural assays, were important in arriving at the appropriate diagnosis of acute leukemia of ambiguous lineage in the new WHO classification.
  • [MeSH-major] Bone Marrow Cells / pathology. Leukemia / pathology. Peroxidase / genetics
  • [MeSH-minor] Acute Disease. Antigens, CD / analysis. Antigens, CD / genetics. Gene Rearrangement. HLA-DR Antigens / analysis. HLA-DR Antigens / genetics. Humans. Immunophenotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1998 Dec;12(12):2038 [9844938.001]
  • [Cites] Ann Intern Med. 1985 Oct;103(4):620-5 [3862359.001]
  • [Cites] Haematologica. 1999 Aug;84(8):699-706 [10457405.001]
  • [Cites] Blood. 1990 Aug 15;76(4):808-13 [2166608.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Leuk Lymphoma. 1999 Jul;34(3-4):395-9 [10439377.001]
  • [Cites] Br J Haematol. 1988 Jun;69(2):205-11 [3390393.001]
  • [Cites] J Exp Med. 1989 Mar 1;169(3):1101-20 [2538542.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Jan;81(1):253-7 [6607471.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1283-7 [8709632.001]
  • (PMID = 16298822.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


55. Malfuson JV, Margery J, Bonnichon A, Fagot T, Souleau B, Samson T, de Revel T: [Acute respiratory distress revealing acute myeloblastic leukaemia: case report]. Rev Pneumol Clin; 2010 Sep;66(4):276-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute respiratory distress revealing acute myeloblastic leukaemia: case report].
  • We report on the case of a patient diagnosed with acute leukaemic transformation of chronic myelomonocytic leukaemia.
  • We discuss the etiologies of respiratory distress in acute myeloblastic leukaemia and the corticosteroid sensitivity of this myeloid disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Leukemia, Myeloid, Acute / diagnosis. Respiratory Distress Syndrome, Adult / etiology
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Glucocorticoids / therapeutic use. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Masson SAS.
  • (PMID = 20933171.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


56. Baruchel A, Leblanc T, Auclerc MF, Schaison G, Leverger G: [Towards cure for all children with acute lymphoblastic leukemia?]. Bull Acad Natl Med; 2009 Oct;193(7):1509-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Towards cure for all children with acute lymphoblastic leukemia?].
  • [Transliterated title] Vers la guérison de tous les enfants atteints de leucémie aiguë lymphoblastique?
  • Childhood acute lymphoblastic leukemia is a model in oncology.
  • The current aims are to de-escalate treatment for better-defined low-risk groups, and to develop the use of new drugs and targeted therapies for high-risk groups, based on genome-wide analysis of the patient and the leukemic cell.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Resistance, Neoplasm. Humans. Immunophenotyping. Infant. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Remission Induction. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669632.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 23
  •  go-up   go-down


57. Thomas X: [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors]. Bull Cancer; 2007 Oct;94(10):871-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
  • [Transliterated title] Leucémie aiguë lymphoblastique à chromosome Philadelphie: traitement par les inhibiteurs de kinases.
  • Distinct clinicopathologic acute lymphoblastic leukemia (ALL) entities have been identified, resulting in the adoption of risk-oriented treatment approaches.
  • The emergence of resistance to the Bcr-Abl inhibitor imatinib mesylate in patients with Philadelphia chromosome-positive (Ph+) ALL has prompted the development of second-generation compounds active against mutant forms, including dasatinib and nilotinib.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein Kinase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964981.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Benzenesulfonates; 0 / Indoles; 0 / Phenylurea Compounds; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 0 / Pyrimidines; 0 / Pyrroles; 0 / Thiazoles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 639089-54-6 / VX680; 8A1O1M485B / Imatinib Mesylate; 9ZOQ3TZI87 / sorafenib; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.- / p21(ras) farnesyl-protein transferase; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  • [Number-of-references] 115
  •  go-up   go-down


58. Ohyashiki JH, Umezu T, Kobayashi C, Hamamura RS, Tanaka M, Kuroda M, Ohyashiki K: Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes; 2010;3:347
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.
  • Our aim was to determine the biological relevance of miR-92a, which has been implicated as an oncomiR in both plasma and leukemia cells in patients with acute leukemia and to evaluate whether it could be a novel biomarker for monitoring these patients.
  • RESULTS: We quantified the expression level of miR-92a in both cells and plasma by reverse transcription polymerase chain reaction in 91 patients with acute leukemia.
  • We compared miR-92a expression in plasma with its expression in leukemia cells.
  • The level of miR-92a expression in fresh leukemia cells was highly variable compared with PBMNC, but significantly lower compared with CD34-positive cells obtained from healthy volunteers.
  • We also noticed that miR-92a was preferentially expressed in acute lymphoblastic leukemia (ALL) cells in comparison with acute myeloid leukemia (AML) cells.
  • Notably, the cell to plasma ratio of miR-92a expression was significantly higher in both AML and ALL cells compared with PBMNC from healthy volunteers.
  • CONCLUSIONS: The miR-92a expression in leukemia cells could be a prognostic factor in ALL patients.
  • The inverse correlation of miR-92a expression between cells and plasma and the cell to plasma ratio may be important to understanding the clinical and biological relevance of miR-92a in acute leukemia.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] Nat Immunol. 2008 Aug;9(8):839-45 [18645592.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5473-7 [19706812.001]
  • [Cites] Blood. 2009 Nov 5;114(19):4169-78 [19749093.001]
  • [Cites] PLoS One. 2009;4(11):e7826 [19915715.001]
  • [Cites] Sci Signal. 2009 Dec 8;2(100):ra81 [19996457.001]
  • [Cites] J Biol Chem. 2010 Jun 4;285(23):17442-52 [20353945.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):743-8 [19672257.001]
  • [Cites] Br J Haematol. 2008 May;141(5):672-5 [18318758.001]
  • [Cites] Cancer Sci. 2008 Jun;99(6):1147-54 [18429962.001]
  • [Cites] Am J Pathol. 2008 Sep;173(3):856-64 [18688024.001]
  • [Cites] Blood. 2009 Jan 8;113(2):396-402 [18941111.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6411-8 [19211935.001]
  • [Cites] Cancer Sci. 2009 May;100(5):970-7 [19298223.001]
  • [Cites] PLoS One. 2009;4(5):e5532 [19440243.001]
  • [Cites] Br J Cancer. 2009 Aug 18;101(4):551-6 [19638982.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] J Interferon Cytokine Res. 2005 Jan;25(1):1-10 [15684617.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Oncogene. 2007 Sep 6;26(41):6099-105 [17384677.001]
  • [Cites] Nucleic Acids Res. 2007 Jul;35(Web Server issue):W339-44 [17553836.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Leuk Res. 2009 Sep;33(9):1217-23 [19195700.001]
  • (PMID = 21182798.001).
  • [ISSN] 1756-0500
  • [Journal-full-title] BMC research notes
  • [ISO-abbreviation] BMC Res Notes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3022817
  •  go-up   go-down


59. Kelly K, Storey L, O' Sullivan M, Butler K, McDermott M, Corbally M, McMahon C, Smith OP, O' Marcaigh A: Esophageal strictures during treatment for acute lymphoblastic leukemia. J Pediatr Hematol Oncol; 2010 Mar;32(2):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esophageal strictures during treatment for acute lymphoblastic leukemia.
  • We describe 4 cases of esophageal stricture during chemotherapy for acute lymphoblastic leukemia.
  • The etiology of esophageal strictures during treatment for acute leukemia is likely to be multifactorial but systemic candidiasis may play a significant role.
  • [MeSH-major] Esophageal Stenosis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20168244.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Antineoplastic Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


60. Koppel A, Schiller G: Myelodysplastic syndrome: an update on diagnosis and therapy. Curr Oncol Rep; 2008 Sep;10(5):372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelodysplastic syndrome: an update on diagnosis and therapy.
  • Despite the variable risk of transformation to acute leukemia, the majority of deaths are due to bone marrow failure.
  • No truly effective treatment exists for MDS, and therapy usually focuses on reducing or preventing complications of the disease.
  • [MeSH-major] Leukemia / diagnosis. Leukemia / therapy. Myelodysplastic Syndromes / diagnosis. Myelodysplastic Syndromes / therapy


61. Heddle NM, Cook RJ, Sigouin C, Slichter SJ, Murphy M, Rebulla P, BEST Collaborative (Biomedical Excellence for Safer Transfusion): A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia. Transfusion; 2006 Jun;46(6):903-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A descriptive analysis of international transfusion practice and bleeding outcomes in patients with acute leukemia.
  • RESULTS: A total of 897 patients with acute leukemia received 10,506 PLT transfusions.
  • [MeSH-major] Hemorrhage / prevention & control. Leukemia / complications. Leukemia / therapy. Platelet Transfusion
  • [MeSH-minor] Acute Disease. Canada. Data Collection. Great Britain. Humans. Incidence. Italy. Platelet Count. Randomized Controlled Trials as Topic. Retrospective Studies. United States


62. Karp JE, Giles FJ, Gojo I, Morris L, Greer J, Johnson B, Thein M, Sznol M, Low J: A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leuk Res; 2008 Jan;32(1):71-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
  • We designed a Phase I trial of Triapine followed by the adenosine analog fludarabine in adults with refractory acute leukemias and aggressive myeloproliferative disorders (MPD).
  • Complete and partial responses (CR, PR) occurred in Schedule A (5/24, 21%), with CR occurring at the 2 highest fludarabine doses (2/12, 17%).
  • In contrast, no CR or PR occurred in Schedule B.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Apr 27;332(17):1132-6 [7700286.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(3):181-8 [7781136.001]
  • [Cites] J Med Chem. 1996 Jun 21;39(13):2586-93 [8691457.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2480-7 [8839839.001]
  • [Cites] Blood. 1997 Jul 1;90(1):270-8 [9207462.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2780-5 [9256119.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2321-31 [9667246.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):647-55 [9722289.001]
  • [Cites] Leuk Res. 2006 Jul;30(7):813-22 [16478631.001]
  • [Cites] Leuk Res. 2007 Sep;31(9):1165-73 [17324462.001]
  • [Cites] Biochem Pharmacol. 2000 Apr 15;59(8):983-91 [10692563.001]
  • [Cites] Leukemia. 2000 Mar;14(3):379-88 [10720130.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3671-4 [11090046.001]
  • [Cites] Prog Biophys Mol Biol. 2001 Nov;77(3):177-268 [11796141.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1369-77 [12168813.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4272-90 [12393615.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1920-8 [12673719.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1077-83 [12921943.001]
  • [Cites] Jpn J Cancer Res. 1985 Aug;76(8):729-35 [3930450.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):74-9 [2416889.001]
  • [Cites] Cancer Treat Rep. 1986 Oct;70(10):1225-8 [2428492.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):329-34 [3335008.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):175-88 [1702143.001]
  • [Cites] Biochem Cell Biol. 1990 Dec;68(12):1364-71 [2085432.001]
  • [Cites] Blood. 1991 Dec 1;78(11):2937-44 [1954383.001]
  • [Cites] Ann Hematol. 1992 Jul;65(1):26-32 [1643157.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):116-24 [8418222.001]
  • [Cites] Blood. 1993 Jul 15;82(2):398-407 [8329700.001]
  • [Cites] J Biol Chem. 1993 Dec 15;268(35):26200-5 [8253740.001]
  • [Cites] J Clin Oncol. 1994 Apr;12(4):671-8 [7512125.001]
  • [Cites] Biochem Pharmacol. 1994 Jul 19;48(2):335-44 [8053929.001]
  • [Cites] Anal Biochem. 1994 Oct;222(1):116-22 [7856836.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4642-9 [14673054.001]
  • [Cites] Cancer Res. 1971 Mar;31(3):235-8 [5102115.001]
  • [Cites] Blood. 1975 Jul;46(1):11-6 [1055610.001]
  • [Cites] Cancer Res. 1980 Sep;40(9):3286-92 [7427943.001]
  • [Cites] Cancer Res. 1983 Jun;43(6):2688-93 [6189585.001]
  • (PMID = 17640728.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070095-14; United States / NCRR NIH HHS / RR / M01-RR0052; United States / NCI NIH HHS / CA / U01 CA70095; United States / NCI NIH HHS / CA / U01 CA070095; United States / NCRR NIH HHS / RR / M01 RR000052; United States / NCI NIH HHS / CA / CA070095-14
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pyridines; 0 / Thiosemicarbazones; 143621-35-6 / 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  • [Other-IDs] NLM/ NIHMS35421; NLM/ PMC2726775
  •  go-up   go-down


63. Watanabe-Okochi N, Oki T, Komeno Y, Kato N, Yuji K, Ono R, Harada Y, Harada H, Hayashi Y, Nakajima H, Nosaka T, Kitaura J, Kitamura T: Possible involvement of RasGRP4 in leukemogenesis. Int J Hematol; 2009 May;89(4):470-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We previously established a mouse bone marrow-derived HF6, an IL-3-dependent cell line, that was immortalized by a class II mutation MLL/SEPT6 and can be fully transformed by class I mutations such as FLT3 mutants.
  • To understand the molecular mechanism of leukemogenesis, particularly progression of myelodysplastic syndrome (MDS) to acute leukemia, we made cDNA libraries from the samples of patients and screened them by expression-cloning to detect class I mutations that render HF6 cells factor-independent.
  • C57BL/6J mice transplanted with RasGRP4-transduced primary bone marrow cells died of T cell leukemia, myeloid leukemia, or myeloid leukemia with T cell leukemia.
  • The double transduction led to early onset of T cell leukemia but not of AML in the transplanted mice when compared to transduction of RasGRP4 alone.
  • Thus, we have identified RasGRP4 as a gene potentially involved in leukemogenesis and suggest that RasGRP4 cooperates with AML1 mutations in T cell leukemogenesis as a class I mutation.
  • [MeSH-major] Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Leukemia / metabolism. Leukemia / pathology. ras Guanine Nucleotide Exchange Factors / metabolism
  • [MeSH-minor] Animals. Cell Line. Cell Proliferation. Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor Alpha 2 Subunit / metabolism. Gene Expression Regulation, Neoplastic. Humans. Mice. Mutation / genetics. Neoplasm Transplantation. Polymorphism, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 15;101(4):1277-83 [12393381.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30508-14 [11880369.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):919-29 [15761502.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2776-84 [17957027.001]
  • [Cites] Leukemia. 2006 Apr;20(4):635-44 [16467864.001]
  • [Cites] Leukemia. 2006 Jun;20(6):965-70 [16598313.001]
  • [Cites] Blood. 2006 Mar 1;107(5):1806-9 [16291592.001]
  • [Cites] Blood. 1999 May 1;93(9):3074-80 [10216104.001]
  • [Cites] Hematol J. 2002;3(6):283-9 [12522450.001]
  • [Cites] Cancer. 2006 Feb 15;106(4):950-6 [16404744.001]
  • [Cites] Br J Haematol. 2003 Jun;121(5):775-7 [12780793.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3768-76 [16105978.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8283-8 [12060771.001]
  • [Cites] Oncogene. 2008 Apr 3;27(15):2249-56 [17968322.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):495-507 [16281942.001]
  • [Cites] Int J Hematol. 1998 Jun;67(4):351-9 [9695408.001]
  • [Cites] Leukemia. 1994 Feb;8(2):258-63 [7508533.001]
  • [Cites] Br J Haematol. 2003 Jan;120(1):89-92 [12492581.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9146-50 [7568090.001]
  • [Cites] Exp Hematol. 2003 Nov;31(11):1007-14 [14585362.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4297-308 [18192504.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1104-9 [15650049.001]
  • [Cites] Leukemia. 2002 Nov;16(11):2185-9 [12399960.001]
  • [Cites] Leukemia. 2005 Oct;19(10 ):1794-805 [16094415.001]
  • [Cites] Curr Opin Hematol. 2002 Jul;9(4):274-81 [12042700.001]
  • [Cites] Blood. 2006 Sep 1;108(5):1708-15 [16675706.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2232-40 [16281072.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2316-24 [14615365.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2492-9 [14562119.001]
  • [Cites] Blood. 2004 Feb 1;103(3):1085-8 [14504097.001]
  • [Cites] Oncogene. 2001 Dec 13;20(57):8236-48 [11781838.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Feb;39(2):110-8 [14695990.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1153-60 [15889156.001]
  • [Cites] Haematologica. 2004 Aug;89(8):920-5 [15339674.001]
  • [Cites] J Biol Chem. 2007 Jun 22;282(25):17997-8008 [17438331.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25756-74 [11956218.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2159-68 [16025155.001]
  • (PMID = 19350351.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RASGRP4 protein, human; 0 / Rasgrp4 protein, mouse; 0 / ras Guanine Nucleotide Exchange Factors
  •  go-up   go-down


64. Uesato N, Fukui K, Maruhashi J, Tojo A, Tajima N: JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Exp Hematol; 2006 Oct;34(10):1385-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model.
  • OBJECTIVE: Accumulating findings suggest that in acute myeloid leukemia (AML) patients, proinflammatory cytokines and growth factors play important roles in the proliferation and survival of AML cells in an autocrine and paracrine manner, leading to deterioration of AML.
  • In the present study, we investigated the potency of JTE-607 as an antileukemic agent by exploiting a SCID mouse acute leukemia model.
  • Delayed administration of JTE-607 also prolonged the survival of mice bearing established leukemia with an effect comparable to the maximum tolerable dose of cytarabine.
  • [MeSH-major] Cytokines / antagonists & inhibitors. Leukemia, Myeloid, Acute / drug therapy. Phenylalanine / analogs & derivatives. Piperazines / pharmacology
  • [MeSH-minor] Animals. Antigens, CD45 / blood. Autocrine Communication / drug effects. Cell Proliferation / drug effects. Disease Models, Animal. Drug Evaluation, Preclinical. Female. Humans. Interleukin-8 / blood. Mice. Mice, SCID. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Paracrine Communication / drug effects. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982331.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-8; 0 / JTE 607; 0 / Piperazines; 47E5O17Y3R / Phenylalanine; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


65. Veneri D, Franchini M, Krampera M, de Matteis G, Solero P, Pizzolo G: Analysis of HFE and TFR2 gene mutations in patients with acute leukemia. Leuk Res; 2005 Jun;29(6):661-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of HFE and TFR2 gene mutations in patients with acute leukemia.
  • We studied the prevalence of 12 hereditary hemochromatosis (HH) gene mutations (C282Y, V53M, V59M, H63D, H63H, S56C, Q127H, E168Q, E168X, W169X and Q283P in the HFE gene and Y250X in the TFR2 gene) and its correlation with the iron status in 82 adult patients with acute leukemia (AL); 48 patients (58.5%) were affected by acute myeloid leukemia (AML) and 34 patients (41.5%) by acute lymphoblastic leukemia (ALL); 27 patients (32.9%) had at least one HH gene mutation (6 heterozygous for C282Y, 6 homozygous for H63D, 13 heterozygous for H63D and 2 heterozygous for S56C).
  • Mean serum ferritin levels at diagnosis were increased (822.5+/-811.4 microg/L).
  • [MeSH-major] Histocompatibility Antigens Class I / genetics. Membrane Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Transferrin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863206.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HFE protein, human; 0 / Histocompatibility Antigens Class I; 0 / Membrane Proteins; 0 / Receptors, Transferrin; 0 / TFR2 protein, human
  •  go-up   go-down


66. Huh JY, Chung S, Oh D, Kang MS, Eom HS, Cho EH, Han MH, Kong SY: Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature. Korean J Lab Med; 2010 Apr;30(2):117-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clathrin assembly lymphoid myeloid leukemia-AF10-positive acute leukemias: a report of 2 cases with a review of the literature.
  • The translocation t(10;11)(p13;q14q21) has been found to be recurrent in acute lymphoblastic and myeloid leukemias, and results in the fusion of the clathrin assembly lymphoid myeloid leukemia (CALM) gene with the AF10 gene; these genes are present on chromosomes 11 and 10, respectively.
  • Because the CALM-AF10 rearrangement is a rare chromosomal abnormality, it is not included in routine molecular tests for acute leukemia.
  • The first patient (case 1) was diagnosed with T-cell ALL, and the second patient (case 2) was diagnosed with AML.
  • Both patient samples showed expression of the homeobox A gene cluster and the histone methyltransferase hDOT1L, which suggests that they mediate leukemic transformation in CALM-AF10-positive and mixed-lineage leukemia-AF10-positive leukemias.
  • The first patient (case 1) relapsed after double-unit cord blood transplantation; there was no evidence of relapse in the second patient (case 2) after allogenic peripheral blood stem cell transplantation.
  • Since CALM-AF10- positive leukemias have been shown to have poor prognosis with conventional therapy, molecular tests for CALM-AF10 rearrangement would be necessary to detect minimal residual disease during follow-up.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Monomeric Clathrin Assembly Proteins / genetics. Oncogene Proteins, Fusion / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 11. Cord Blood Stem Cell Transplantation. Female. Histone-Lysine N-Methyltransferase / genetics. Histone-Lysine N-Methyltransferase / metabolism. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Male. Recurrence. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445327.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MLLT10 protein, human; 0 / Monomeric Clathrin Assembly Proteins; 0 / Oncogene Proteins, Fusion; 0 / PICALM protein, human; 0 / Transcription Factors; EC 2.1.1.- / histone methyltransferase; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 14
  •  go-up   go-down


67. Schalk E, Mohren M, Jentsch-Ullrich K, Dombrowski F, Franke A, Koenigsmann M: Zygomycoses in patients with acute leukaemia. Ann Hematol; 2006 May;85(5):327-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zygomycoses in patients with acute leukaemia.
  • The high mortality rate is due to a high failure rate of both intravital diagnosis and treatment.
  • Exact diagnosis requires microscopic examination and proof by culture.
  • We report four recent cases of zygomycosis among 89 patients with intensively treated acute leukaemia at our institution.
  • Three cases were breakthrough infections since the patients were under voriconazole treatment prior to diagnosis of zygomycosis.
  • Only one patient had premortal diagnosis (paranasal sinus infection) and showed clinical response with amphotericin B and surgical debridement.
  • A review of the literature of these emerging fungal infections is given and is focused on patients with acute leukaemia.
  • [MeSH-major] Amphotericin B / administration & dosage. Antifungal Agents / administration & dosage. Immunocompromised Host. Leukemia. Zygomycosis / diagnosis. Zygomycosis / therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523312.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Pyrimidines; 0 / Triazoles; 7XU7A7DROE / Amphotericin B; JFU09I87TR / Voriconazole
  • [Number-of-references] 39
  •  go-up   go-down


68. Robinson BW, Felix CA: Panhandle PCR approaches to cloning MLL genomic breakpoint junctions and fusion transcript sequences. Methods Mol Biol; 2009;538:85-114
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Translocations and other rearrangements of the MLL gene at chromosome band 11q23 are biologically and clinically important molecular abnormalities in infant acute leukemias, leukemias associated with chemotherapeutic topoisomerase II poisons and, less often, acute leukemias in adults or myelodysplastic syndrome.
  • Depending on the disease and the regimen, MLL-rearranged leukemias may be associated with inferior prognosis, and MLL rearrangements with some of the more than 60 known MLL-partner genes confer especially adverse effects as response to treatment (Blood 108:441-451, 2006).
  • MLL rearrangements are usually evident as overt balanced chromosomal translocations by conventional cytogenetic analysis but up to one-third are cryptic rearrangements and occur in leukemias with del(11)(q23), a normal karyotype, or trisomy 11, the latter two of which sometimes are associated with partial tandem duplications of MLL itself (Proc Natl Acad Sci USA 97:2814-2819, 2000; Proc Natl Acad Sci USA 94:3899-3902, 1997).
  • Rapid and accurate methods to identify and characterize genomic breakpoint junctions and fusion transcripts resulting from the many types of MLL rearrangements are essential for risk group stratification, treatment protocol assignments, new partner gene discovery, understanding leukemia etiology and pathogenesis, and elucidating the impact of less common MLL-partner genes on biology and prognosis.
  • Due to the vast heterogeneity in partner genes, typical gene-specific PCR based methods are not practical, especially when cytogenetics are normal or do not suggest involvement of a known partner gene of MLL.
  • [MeSH-major] Chromosome Breakage. Cloning, Molecular / methods. Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics. Oncogene Proteins, Fusion / genetics. Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277575.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA77683; United States / NCI NIH HHS / CA / CA80175; United States / NCI NIH HHS / CA / CA85469
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


69. Zhou L, Guo X, Jing BA, Zhao L: CD44 is involved in CXCL-12 induced acute myeloid leukemia HL-60 cell polarity. Biocell; 2010 Aug;34(2):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD44 is involved in CXCL-12 induced acute myeloid leukemia HL-60 cell polarity.
  • CXCL-12 and its receptor CXCR4 participate in breast cancer and melanoma cell metastasis to bone and lymphoid nodes.
  • But the role of CD44 in CXCL-12 induced leukemia cell migration still remains unclear.
  • The present study showed that CXCL-12 stimulation induced the rapid internalization of CXCR4 and facilitated the formation of lamellipodia and uropod in acute leukemia cell line HL-60.
  • CXCL-12 also induced CD44 translocation into the uropod, while CD44 remained evenly distributed on the untreated cell membranes.
  • Results suggest that CD44 participates in CXCL-12 induced cell polarization and subsequent cell migration.
  • [MeSH-major] Antigens, CD44 / immunology. Cell Polarity. Chemokine CXCL12 / immunology. Leukemia, Myeloid, Acute / immunology
  • [MeSH-minor] Animals. Cell Movement / physiology. Cell Surface Extensions / metabolism. HL-60 Cells. Humans. Receptors, CXCR4

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925198.001).
  • [ISSN] 0327-9545
  • [Journal-full-title] Biocell : official journal of the Sociedades Latinoamericanas de Microscopía Electronica ... et. al
  • [ISO-abbreviation] Biocell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR4
  •  go-up   go-down


70. Zee YK, Soo RA: Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse. Int J Infect Dis; 2010 Jun;14(6):e518-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-small cell lung cancer presenting with neoplastic fever at diagnosis and relapse.
  • Fever occurs frequently in cancer patients, and neoplastic fever is a well-described paraneoplastic phenomenon in patients with lymphoma, acute leukemias, and renal cell carcinoma.
  • It is also more commonly encountered in metastatic disease.
  • Treatment options include disease-specific therapy, non-steroidal anti-inflammatory drugs (NSAIDs), and steroids.
  • In this report, we describe an unusual case of non-metastatic non-small cell lung cancer (NSCLC) presenting with neoplastic fever at both diagnosis and relapse, responding on each occasion to disease-specific treatment, and provide a review of the management of neoplastic fever.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Fever / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19699672.001).
  • [ISSN] 1878-3511
  • [Journal-full-title] International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
  • [ISO-abbreviation] Int. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


71. Ravandi F, Kebriaei P: Cytokines in the treatment of acute leukemias. Cancer Treat Res; 2005;126:313-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokines in the treatment of acute leukemias.
  • [MeSH-major] Cytokines / therapeutic use. Leukemia / therapy
  • [MeSH-minor] Acute Disease. Humans

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16209072.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 88
  •  go-up   go-down


72. Glatting G, Müller M, Koop B, Hohl K, Friesen C, Neumaier B, Berrie E, Bird P, Hale G, Blumstein NM, Waldmann H, Bunjes D, Reske SN: Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. J Nucl Med; 2006 Aug;47(8):1335-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
  • The outcome of hematopoietic cell transplantation for hematologic malignancies may be improved by delivering targeted radiation to hematopoietic organs while relatively sparing nontarget organs.
  • [MeSH-major] Antibodies, Monoclonal / chemistry. Antigens, CD45 / chemistry. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Bone Marrow Transplantation. Female. Humans. Male. Middle Aged. Stem Cell Transplantation. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883014.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G7904009
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / YAML568 monoclonal antibody; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


73. Vollmer RT: Blast counts in bone marrow aspirate smears: analysis using the poisson probability function, bayes theorem, and information theory. Am J Clin Pathol; 2009 Feb;131(2):183-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blast counts in bone marrow aspirate smears: analysis using the poisson probability function, bayes theorem, and information theory.
  • Herein, I introduce and demonstrate these mathematical functions for the analysis of counts of blasts in marrow aspirates and explore the uncertainty that naturally arises when counts of blasts are near cut points used to separate the categories of refractory anemia without excess blasts, refractory anemia with excess blasts, and acute leukemia.
  • [MeSH-major] Anemia, Refractory, with Excess of Blasts / diagnosis. Bayes Theorem. Bone Marrow Cells / pathology. Cell Count / statistics & numerical data. Leukemia / diagnosis. Poisson Distribution. Probability

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Clin Pathol. 2009 Jul;132(1):147-8; author reply 148 [19864247.001]
  • (PMID = 19141378.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] United States
  •  go-up   go-down


74. Shahsavar F, Tajik N, Entezami KZ, Fallah Radjabzadeh M, Asadifar B, Alimoghaddam K, Ostadali Dahaghi M, Jalali A, Ghashghaie A, Ghavamzadeh A: KIR2DS3 is associated with protection against acute myeloid leukemia. Iran J Immunol; 2010 Mar;7(1):8-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KIR2DS3 is associated with protection against acute myeloid leukemia.
  • BACKGROUND: Interaction between killer cell immunoglobulin-like receptors (KIR) and human leukocyte antigen (HLA) class I molecules is important for regulation of natural killer (NK) cell function.
  • OBJECTIVE: The aim of this study was to investigate the impact of compound KIR-HLA genotype on susceptibility to acute leukemia.
  • METHODS: Cohorts of Iranian patients with acute myeloid leukemia (AML; n=40) and acute lymphoid leukemia (ALL; n=38) were genotyped for seventeen KIR genes and their three major HLA class I ligand groups (C1, C2, Bw4) by a combined polymerase chain reaction-sequence-specific primers (PCR-SSP) assay.
  • Other analyses including KIR genotypes, distribution and balance of inhibitory and activating KIR+HLA combinations, and co-inheritance of activating KIR genes with inhibitory KIR+HLA pairs were not significantly different between leukemia patients and the control group.
  • CONCLUSION: Our findings may suggest a mechanism for escape of leukemic cells from NK cell immunity.
  • [MeSH-major] Genetic Predisposition to Disease. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / immunology. Receptors, KIR / genetics. Receptors, KIR / immunology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371915.001).
  • [ISSN] 1735-1383
  • [Journal-full-title] Iranian journal of immunology : IJI
  • [ISO-abbreviation] Iran J Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KIR2DS3 protein, human; 0 / Ligands; 0 / Receptors, KIR
  •  go-up   go-down


75. Xavier AC, Ge Y, Taub JW: Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn; 2009 Sep;11(5):371-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DS children have a approximately 10- to 20-fold higher risk for developing acute lymphoblastic leukemia and acute myeloid leukemia (AML), as compared with non-DS children, although they do not have a uniformly increased risk of developing solid tumors.
  • DS children with acute lymphoblastic leukemia frequently experience higher levels of treatment-related toxicity and inferior event-free survival rates, as compared with non-DS children.
  • DS children also develop AML with unique features and have a 500-fold increased risk of developing the AML subtype, acute megakaryocytic leukemia (AMkL; M7).
  • Nearly 10% of DS newborns are diagnosed with a variant of AMkL, the transient myeloproliferative disorder, which can resolve spontaneously without treatment; event-free survival rates for DS patients with AMkL ranges from 80% to 100%, in comparison with <30% for non-DS children with AMkL.
  • In addition, somatic mutations of the GATA1 gene have been detected in nearly all DS TMD and AMkL cases and not in leukemia cases in non-DS children.
  • Examining leukemogenesis in DS children may identify factors linked to the general development of childhood leukemia and lead to potential new therapeutic strategies to fight this disease.
  • [MeSH-minor] Animals. Disease-Free Survival. GATA1 Transcription Factor / genetics. Humans. Leukemia, Megakaryoblastic, Acute / epidemiology. Leukemia, Megakaryoblastic, Acute / etiology. Leukemia, Megakaryoblastic, Acute / genetics. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2008 Aug;93(8):1262-3 [18519512.001]
  • [Cites] Br J Haematol. 2008 Aug;142(4):610-5 [18510680.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2572-7 [18829445.001]
  • [Cites] Leukemia. 2008 Oct;22(10):1813-7 [18754026.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Pediatr Blood Cancer. 2009 Jan;52(1):14-9 [18802938.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4507-11 [18689547.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4503-6 [18812473.001]
  • [Cites] Eur J Haematol. 2009 Jan;82(1):46-53 [19067745.001]
  • [Cites] Blood. 2009 Jan 15;113(3):646-8 [18927438.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1575-83 [17971484.001]
  • [Cites] Blood. 2002 Jan 1;99(1):245-51 [11756178.001]
  • [Cites] Leuk Res. 1994 Mar;18(3):163-71 [8139285.001]
  • [Cites] Med Pediatr Oncol. 1995 May;24(5):305-9 [7700182.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3395-403 [8605357.001]
  • [Cites] N Engl J Med. 1996 May 30;334(22):1428-34 [8618581.001]
  • [Cites] Med Hypotheses. 1996 Apr;46(4):393-9 [8733171.001]
  • [Cites] Eur J Hum Genet. 2001 Nov;9(11):811-4 [11781696.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):428-36 [11794699.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):147-52 [11809723.001]
  • [Cites] Bull Acad Natl Med. 2001;185(7):1239-52; discussion 1252-4 [11975321.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):148-52 [12172547.001]
  • [Cites] Leukemia. 2003 Feb;17(2):277-82 [12592323.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):930-8 [12648061.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):197-9 [12714896.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4301-4 [12586620.001]
  • [Cites] Blood. 2003 Aug 1;102(3):981-6 [12649131.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3415-22 [12885836.001]
  • [Cites] Blood. 2004 Jan 1;103(1):366 [14684662.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):728-35 [14744791.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2480-9 [14656875.001]
  • [Cites] Leuk Lymphoma. 2004 Jan;45(1):19-25 [15061193.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1588-9 [15317736.001]
  • [Cites] Lancet. 1986 Oct 18;2(8512):914 [2876340.001]
  • [Cites] Eur J Pediatr. 1987 Jul;146(4):416-22 [2958283.001]
  • [Cites] Am J Med Genet Suppl. 1990;7:204-12 [2149949.001]
  • [Cites] Br J Cancer. 1991 Jun;63(6):993-9 [2069856.001]
  • [Cites] Blood. 1992 Nov 1;80(9):2210-4 [1384797.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1266-9 [9182298.001]
  • [Cites] Cell. 1997 Jul 11;90(1):109-19 [9230307.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3965-73 [9233806.001]
  • [Cites] Blood. 1998 Jan 15;91(2):608-15 [9427716.001]
  • [Cites] Cancer Res. 1998 Feb 1;58(3):448-52 [9458088.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1393-400 [10438727.001]
  • [Cites] J Biol Chem. 2004 Nov 26;279(48):50537-54 [15448146.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1866-72 [15520821.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):21-8 [15368546.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):33-9 [15390307.001]
  • [Cites] Semin Cell Dev Biol. 2005 Feb;16(1):137-47 [15659348.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):226-31 [15687366.001]
  • [Cites] Br J Haematol. 2005 Mar;128(6):797-804 [15755283.001]
  • [Cites] Nat Genet. 2005 Jun;37(6):613-9 [15895080.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):405-10 [15952191.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Apr-May;22(3):229-34 [16020107.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1355-60 [15920490.001]
  • [Cites] Leuk Res. 2005 Nov;29(11):1353-6 [15916804.001]
  • [Cites] Ophthalmic Genet. 2005 Sep;26(3):151-2 [16272063.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4043-9 [16109782.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):748-52 [16356424.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jan 6;54(51):1301-5 [16397457.001]
  • [Cites] Leukemia. 2006 Feb;20(2):381-3 [16341038.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):576-83 [16445830.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1570-81 [16249385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):646-8 [16704441.001]
  • [Cites] J Pediatr. 2006 May;148(5):687-9 [16737888.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4606-13 [16469874.001]
  • [Cites] Pediatrics. 2006 Nov;118(5):e1499-508 [17030598.001]
  • [Cites] Pediatr Blood Cancer. 2007 Oct 15;49(5):624-8 [17610268.001]
  • [Cites] Blood. 2007 Sep 15;110(6):2128-31 [17576817.001]
  • [Cites] Cancer. 2007 Nov 1;110(9):2067-74 [17849462.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5442-7 [18048827.001]
  • [Cites] Nature. 2008 Jan 3;451(7174):73-5 [18172498.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):414-20 [18202418.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Leukemia. 2000 May;14(5):943-4 [10803530.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):175-8 [11305722.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3727-32 [11389009.001]
  • [Cites] Blood. 2001 Jul 1;98(1):85-92 [11418466.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;67:131-62 [11525381.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2681-8 [11675338.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2991-8 [18182574.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1428-30 [18059480.001]
  • [Cites] Cancer. 2008 Aug 1;113(3):515-21 [18521927.001]
  • (PMID = 19710397.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120772
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human
  • [Number-of-references] 87
  • [Other-IDs] NLM/ PMC2729834
  •  go-up   go-down


76. Hu SY, Chen ZX, Gu WY, Cen JN, Zhao Y, Gu M: [Detection of RbAp46 expression in bone marrow cells of leukemia patients by real-time quantitative RT-PCR]. Zhonghua Xue Ye Xue Za Zhi; 2005 Jul;26(7):417-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of RbAp46 expression in bone marrow cells of leukemia patients by real-time quantitative RT-PCR].
  • OBJECTIVE: To investigate retinoblastoma (Rb) associated protein 46 (RbAp46) gene expression levels in bone marrow (BM) cells of leukemia patients.
  • METHODS: Real-time quantitative reverse polymerase chain reaction (QRT-PCR) method was used for detecting RbAp46 expression levels in BM cells of 140 patients with acute leukemia (AL), 13 with chronic myelogenous leukemia in chronic phase (CML-CP), 7 with CML in blast crisis (CML-BC) and 32 with non-leukemic disorders.
  • RESULTS: The M-Estimators of RbAp46 were higher in 98 newly diagnosed ALs and 5 relapsed ALs than in 28 ALs in complete remission (CR) and 32 non-leukemic controls (178.23 and 213.65 vs 85.89 and 88.08, respectively).
  • CONCLUSION: RbAp46 expression levels in ALs and CML-BC were strikingly higher than that in non-leukemias and CML-CP, and might participate in leukemogenesis.
  • [MeSH-major] Carrier Proteins / genetics. Leukemia / genetics. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251025.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Nuclear Proteins; 0 / RBBP7 protein, human; 0 / Retinoblastoma-Binding Protein 7
  •  go-up   go-down


77. Ramanarayanan J, Mehdi S, Brodzik F, Pasquale D: Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib. Hematology; 2007 Dec;12(6):505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
  • Imatinib, a selective ABL kinase inhibitor has improved therapeutic outcome in patients with Philadelphia positive chronic or acute leukemia.
  • In the present study, we describe a 56-year-old male with Philadelphia chromosome positive acute lymphocytic leukemia (ALL) who was treated with up-front single agent imatinib and achieved complete hematologic, cytogenetic and molecular remission.
  • At relapse 11 months later, new chromosomal translocations involving chromosomes 1, 7 and 4 and cryptic addition to chromosome 11 were identified in Ph+ cells and the patient had rapid deterioration with progressive disease.
  • The significance of additional chromosomal abnormalities in imatinib treated patients and secondary chromosomal abnormalities in Philadelphia positive chronic myeloid leukemia and ALL are discussed briefly in this report.
  • [MeSH-major] Chromosomes, Human, Pair 11. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Pyrimidines / therapeutic use. Thiazoles / therapeutic use. Translocation, Genetic

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852464.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Thiazoles; 8A1O1M485B / Imatinib Mesylate; RBZ1571X5H / Dasatinib
  •  go-up   go-down


78. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, Reuter S, von Baum H, Marre R: Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis; 2005 Feb;24(2):111-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia.
  • The aim of the present study was to investigate the epidemiologic evolution of fluoroquinolone resistance of E. coli clinical isolates from patients admitted to a hematology-oncology service where fluoroquinolone prophylaxis during neutropenia was recommended as the standard of care for many years but was then discontinued in a trial conducted in patients with acute leukemia.
  • Epidemiologic surveillance of fluoroquinolone resistance of E. coli clinical isolates at our cancer center since 1992 showed a continuing influx of new clones not previously observed in the population of cancer patients, an increase in the number of cancer patients per year colonized and/or infected by fluoroquinolone-resistant E. coli (1992-1994, 10-16 patients; 1995-1997, 24-27 patients), and a resistance rate of >50% among E. coli bloodstream isolates of hematology-oncology patients.
  • A 6-month fluoroquinolone prophylaxis discontinuation intervention trial in 1998 suggested that despite increasing resistance among E. coli isolates, fluoroquinolone prophylaxis in acute leukemia patients was still effective in the prevention of gram-negative bacteremia (incidence rates, 8% during the pre-intervention period vs. 20% after discontinuation; p<0.01).
  • The resumption of fluoroquinolone prophylaxis in acute leukemia patients thereafter decreased the incidence of gram-negative bacteremia to the pre-intervention level (9%; p=0.03), while the proportion of in vitro fluoroquinolone resistance in E. coli bacteremia isolates again increased (from 15% during the intervention period to >50% in the post-intervention period).
  • [MeSH-major] Anti-Infective Agents / pharmacology. Drug Resistance, Bacterial. Escherichia coli / drug effects. Escherichia coli Infections / prevention & control. Fluoroquinolones / pharmacology. Leukemia / complications. Neutropenia / complications

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):109-10 [15714331.001]
  • [Cites] Clin Lab Haematol. 2001 Feb;23 (1):39-42 [11422229.001]
  • [Cites] Clin Infect Dis. 1997 Aug;25(2):346-8 [9332551.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Dec;10(6):895-903 [11798516.001]
  • [Cites] Schweiz Med Wochenschr. 2000 Dec 2;130(48):1837-44 [11132527.001]
  • [Cites] Clin Infect Dis. 2002 Mar 15;34(6):730-51 [11850858.001]
  • [Cites] Am J Med. 1994 Sep;97(3):256-64 [8092175.001]
  • [Cites] Indian J Med Res. 2001 Dec;114:207-11 [12040764.001]
  • [Cites] Leuk Lymphoma. 1999 Aug;34(5-6):585-9 [10492083.001]
  • [Cites] J Antimicrob Chemother. 1992 Nov;30(5):730-1 [1493993.001]
  • [Cites] Clin Infect Dis. 1997 Dec;25(6):1385-91 [9431383.001]
  • [Cites] Clin Infect Dis. 1999 Sep;29(3):490-4 [10530434.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Feb;40(2):503-5 [8834911.001]
  • [Cites] N Engl J Med. 1994 Apr 28;330(17):1240-1 [8139646.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):27-33 [10037047.001]
  • [Cites] J Antimicrob Chemother. 1988 Dec;22(6):953-4 [3149635.001]
  • [Cites] Vet Microbiol. 1998 Nov;64(1):75-81 [9874105.001]
  • [Cites] Clin Microbiol Infect. 1999 Aug;5(8):457-461 [11856289.001]
  • [Cites] Infection. 1991 Mar-Apr;19(2):73-80 [2050424.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1359-68 [11762805.001]
  • [Cites] Med Clin (Barc). 2003 Mar 15;120(9):321-5 [12646106.001]
  • [Cites] Curr Clin Top Infect Dis. 1988;9:1-43 [3077285.001]
  • [Cites] Emerg Infect Dis. 2001 Sep-Oct;7(5):862-71 [11747700.001]
  • [Cites] Clin Infect Dis. 1998 Jul;27(1):235-7 [9675498.001]
  • [Cites] Bone Marrow Transplant. 2004 Apr;33(8):847-53 [14755314.001]
  • [Cites] Clin Infect Dis. 1995 Apr;20(4):907-12 [7795093.001]
  • [Cites] Oncol Rep. 1994 Nov;1(6):1101-5 [21607499.001]
  • [Cites] Clin Infect Dis. 1995 Mar;20(3):557-60; discussion 561-3 [7756475.001]
  • [Cites] J Med Microbiol. 1997 Jun;46(6):506-10 [9350204.001]
  • [Cites] Intern Med. 1993 Sep;32(9):710-5 [8142675.001]
  • [Cites] Infection. 1998 Nov-Dec;26(6):379-84 [9861564.001]
  • [Cites] Acta Haematol. 1998;99(4):206-11 [9644298.001]
  • [Cites] Br J Haematol. 2001 Oct;115(1):46-52 [11722408.001]
  • [Cites] Clin Infect Dis. 1996 Oct;23(4):795-805 [8909847.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Apr;38(4):681-7 [8031031.001]
  • [Cites] Eur J Cancer. 1992;28A(4-5):873-8 [1524913.001]
  • [Cites] Lung Cancer. 1998 Feb;19(2):121-5 [9567248.001]
  • [Cites] Ann Intern Med. 1987 Jan;106(1):7-11 [3466563.001]
  • [Cites] Enferm Infecc Microbiol Clin. 2001 Nov;19(9):422-7 [11709119.001]
  • [Cites] Ann Intern Med. 1996 Aug 1;125(3):183-90 [8686975.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):1005-11 [8164024.001]
  • [Cites] Med Clin (Barc). 1994 Jan 29;102(3):81-5 [8133717.001]
  • [Cites] J Antimicrob Chemother. 1999 Jul;44(1):117-20 [10459819.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Mar;38(3):465-72 [8203838.001]
  • [Cites] Transplantation. 1991 Mar;51(3):630-6 [2006519.001]
  • [Cites] Antimicrob Agents Chemother. 1993 Mar;37(3):474-82 [8460916.001]
  • [Cites] Infection. 2000 Sep;28(5):278-81 [11073133.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):419-24 [12518366.001]
  • [Cites] Clin Infect Dis. 2002 Jun 1;34(11):1469-74 [12015693.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2001 Sep;20(9):657-60 [11714050.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1998 Aug;17(8):591-2 [9796662.001]
  • [Cites] Bone Marrow Transplant. 1999 Dec;24(11):1207-11 [10642810.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1179-87 [9508206.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):93-7 [3132393.001]
  • [Cites] Antimicrob Agents Chemother. 1990 Feb;34(2):215-8 [2327768.001]
  • [Cites] Lancet. 1997 Feb 8;349(9049):403 [9033478.001]
  • [Cites] Antimicrob Agents Chemother. 1996 Feb;40(2):387-92 [8834885.001]
  • [Cites] J Clin Oncol. 2000 May;18(10):2126-34 [10811678.001]
  • (PMID = 15714332.001).
  • [ISSN] 0934-9723
  • [Journal-full-title] European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • [ISO-abbreviation] Eur. J. Clin. Microbiol. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Fluoroquinolones
  •  go-up   go-down


79. Dinçol G, Palandüz S, Nalçaci M, Uçur A, Büyükaydin B: Myeloid/natural killer cell precursor acute leukemia with tetraploidy. Cancer Genet Cytogenet; 2005 Dec;163(2):156-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid/natural killer cell precursor acute leukemia with tetraploidy.
  • Myeloid/natural killer (NK) cell precursor acute leukemia is characterized by coexpression of myeloid and natural killer cell antigens and an aggressive clinical course.
  • Here we report a case of myeloid/NK precursor acute leukemia in a 37-year-old woman.
  • Clinical presentation was correlated with leukemic blast morphology, immunophenotype, and cytogenetic analysis.
  • Peripheral blood smears and bone marrow aspirate smears at presentation revealed blastic cells, which were generally L2 shaped, with variation in cell size, round to moderately irregular nuclei and prominent nucleoli, pale cytoplasm, and a lack of azurophilic granules.
  • Immunophenotypic analysis of the blasts displayed coexpression of myeloid and natural killer cell antigens with relatively immature phenotype: CD7+, CD33+, CD34+, CD56+, CD57+, CD16-, MPO-.
  • Fluorescence in situ hybridization analysis revealed the same abnormality.
  • The patient did not respond to chemotherapy (cytosine arabinoside and idarubicin) and died of a septic complication on the 34th day after admission.
  • To our knowledge, this is the first description of tetraploidy in myeloid/NK cell precursor acute leukemia.
  • [MeSH-major] Killer Cells, Natural / immunology. Leukemia, Myeloid / genetics. Polyploidy
  • [MeSH-minor] Acute Disease. Adult. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Karyotyping

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Tetraploidy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16337859.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Nguyen-Khac F, Davi F, Receveur A, Maloum K, Morel V, Le Garff-Tavernier M, Ong J, Berger R, Leblond V, Merle-Béral H: Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin. Cancer Genet Cytogenet; 2005 May;159(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt-type acute leukemia in a patient with B-prolymphocytic leukemia: evidence for a common origin.
  • Burkitt-type acute leukemia cells were present in the bone marrow of a patient with B-prolymphocytic leukemia diagnosed from peripheral blood cell morphology.
  • These data indicated the common origin of the two coexisting leukemias and are the first example of such occurrence in a leukemic patient.
  • [MeSH-major] Burkitt Lymphoma / genetics. Chromosomes, Human, Pair 22 / genetics. Chromosomes, Human, Pair 8 / genetics. Leukemia, Prolymphocytic / genetics. Neoplasms, Second Primary / genetics. Translocation, Genetic
  • [MeSH-minor] Bone Marrow / pathology. Cell Lineage. Cytogenetic Analysis. Female. Gene Rearrangement. Genes, myc. Humans. In Situ Hybridization, Fluorescence. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Li ZY, Liu DP, Liang CC: New insight into the molecular mechanisms of MLL-associated leukemia. Leukemia; 2005 Feb;19(2):183-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New insight into the molecular mechanisms of MLL-associated leukemia.
  • Rearrangements of the MLL gene (ALL1, HRX, and Hrtx) located at chromosome band 11q23 are commonly involved in adult and pediatric cases of primary acute leukemias and also found in cases of therapy-related secondary leukemias.
  • Studies on mouse models of MLL translocation and cell lines containing MLL rearrangements showed that the MLL gene linked chromosomal rearrangements to cellular differentiation and tumor tropism.
  • [MeSH-major] DNA-Binding Proteins / genetics. Leukemia / genetics. Proto-Oncogenes / genetics. Transcription Factors / genetics
  • [MeSH-minor] Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Mutation. Myeloid-Lymphoid Leukemia Protein. Zinc Fingers / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15618964.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 89
  •  go-up   go-down


82. Rahman MM, Khan MA: Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia. Bangladesh Med Res Counc Bull; 2009 Dec;35(3):91-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia.
  • Infection in chemotherapy-induced neutropenia (neutrophils < 500/mm3) is the main cause of death during the treatment of acute leukemia.
  • Eighty patients of acute leukemia was randomly assigned to had levofoxacin (500 mg/daily) or placebo from the starting of chemotherapy.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Antineoplastic Agents / adverse effects. Bacterial Infections / prevention & control. Leukemia / blood. Leukemia / microbiology. Levofloxacin. Neutropenia / microbiology. Ofloxacin / therapeutic use
  • [MeSH-minor] Acute Disease. Adult. Antibiotic Prophylaxis. Female. Humans. Male. Single-Blind Method

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. Levofloxacin .
  • Hazardous Substances Data Bank. Ofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922911.001).
  • [ISSN] 0377-9238
  • [Journal-full-title] Bangladesh Medical Research Council bulletin
  • [ISO-abbreviation] Bangladesh Med Res Counc Bull
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Bangladesh
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 6GNT3Y5LMF / Levofloxacin; A4P49JAZ9H / Ofloxacin
  •  go-up   go-down


83. Hashii Y, Sato E, Ohta H, Oka Y, Sugiyama H, Ozono K: WT1 peptide immunotherapy for cancer in children and young adults. Pediatr Blood Cancer; 2010 Aug;55(2):352-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the efficacy of WT1 vaccination for five children with solid cancer or acute leukemia.
  • One patient showed complete response and one patient showed stable disease according to the Response Evaluation Criteria in Solid Tumors; the remaining three showed progressive disease.
  • These results suggest that WT1 vaccination has therapeutic potential, but any beneficial effect may be insufficient in the presence of gross residual disease.
  • [MeSH-minor] Adolescent. Child. Erythema / chemically induced. Female. HLA-A Antigens. HLA-A24 Antigen. Humans. Leukemia / therapy. Male. Peptide Fragments / administration & dosage. Peptide Fragments / therapeutic use. T-Lymphocytes, Cytotoxic / immunology. Treatment Outcome. Vaccination. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582983.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-A Antigens; 0 / HLA-A*24:02 antigen; 0 / HLA-A24 Antigen; 0 / Peptide Fragments; 0 / WT1 Proteins
  •  go-up   go-down


84. Xicoy B, Ribera JM, Oriol A, Sanz MA, Abella E, Tormo M, del Potro E, Bueno J, Grande C, Fernández-Calvo J, Orts M, Novo A, Rivas C, Hernández-Rivas JM, Feliu E, Ortega JJ: [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients]. Med Clin (Barc); 2006 Jan 21;126(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic influence of immunological subtypes of T-cell acute lymphoblastic leukemia. Study of 81 patients].
  • [Transliterated title] Significado pronóstico de los subtipos inmunológicos de la leucemia aguda linfoblástica T del adulto. Estudio de 81 pacientes.
  • BACKGROUND AND OBJECTIVE: T-cell acute lymphoblastic leukemia (ALL) includes 4 immunological subtypes: pro-T, pre-T, thymic or cortical and mature.
  • The objective of this study was to describe the clinical characteristics, the result of treatment and the prognosis of the immunological subtypes of T-cell ALL in 81 adult patients included in 2 protocols of the Spanish PETHEMA group (ALL-96 and ALL-93).
  • The main clinical and biological parameters as well as the rate of response to treatment, the frequency of complete remission , disease free survival and overall survival were compared in each T-cell ALL subtype.
  • Patients with mature T-cell ALL had a slow rate of response to treatment in comparison with patients wit pre-T and mature T-cell ALL but this did not translate to significant differences in frequency of complete remission (77% vs 94%), disease free survival (42% vs 46%) and overall survival (29% vs 47%).
  • CONCLUSIONS: Although patients with mature T-cell ALL had a slow rate of response to treatment and their survival tended to be shorter, in the present study there were no statistically significant differences in the prognosis of the different subtypes of T-cell ALL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426542.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


85. Hernández-Morales AL, Zonana-Nacach A, Zaragoza-Sandoval VM: [Associated risk factors in acute leukemia in children. A cases and controls study]. Rev Med Inst Mex Seguro Soc; 2009 Sep-Oct;47(5):497-503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Associated risk factors in acute leukemia in children. A cases and controls study].
  • [Transliterated title] Factores asociados a leucemia aguda en niños. Estudio de casos y controles.
  • OBJECTIVE: To investigate the risk factors associated with childhood acute leukemia (CHAL).
  • A non-significant frequency was observed with previous fetal death, neonatal jaundice, smoking 3 months before pregnancy, father intake of alcohol, pesticides use during pregnancy at home or garden and living close (< 60 m) to agricultural fields.
  • [MeSH-major] Leukemia, Myeloid, Acute. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20550859.001).
  • [ISSN] 0443-5117
  • [Journal-full-title] Revista médica del Instituto Mexicano del Seguro Social
  • [ISO-abbreviation] Rev Med Inst Mex Seguro Soc
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


86. Della Porta MG, Malcovati L, Boveri E, Travaglino E, Pietra D, Pascutto C, Passamonti F, Invernizzi R, Castello A, Magrini U, Lazzarino M, Cazzola M: Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol; 2009 Feb 10;27(5):754-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
  • CD34+ cell clusters were found in 23% of patients and were associated with WHO categories with excess of blasts (P < .001) and poor-risk cytogenetics (P = .001).
  • In multivariable analysis, BM fibrosis and presence of CD34+ cell clusters had independent negative impact on overall survival (P < .001 and P = .019, respectively) and leukemia-free survival (P < .001 and P = .004, respectively).
  • One cluster consisted mainly of patients with BM fibrosis, multilineage dysplasia, and high transfusion requirement; these individuals had lower overall survival and leukemia-free survival (P = .001 and P < .001, respectively).
  • Furthermore, the presence of CD34+ cell clusters is an independent risk factor for progression to acute leukemia.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Fibrosis. Humans. Leukemia, Myelomonocytic, Acute / pathology. Male. Middle Aged. Prognosis. Retrospective Studies


87. Kaufmann SH, Karp JE, Letendre L, Kottke TJ, Safgren S, Greer J, Gojo I, Atherton P, Svingen PA, Loegering DA, Litzow MR, Sloan JA, Reid JM, Ames MM, Adjei AA, Erlichman C: Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia. Clin Cancer Res; 2005 Sep 15;11(18):6641-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I and pharmacologic study of infusional topotecan and Carboplatin in relapsed and refractory acute leukemia.
  • PURPOSE: To assess the maximum tolerated dose, toxicities, pharmacokinetics, and antileukemic activity of topotecan and carboplatin in adults with recurrent or refractory acute leukemias.
  • Among 45 evaluable patients, there were 7 complete remissions, 2 partial remissions, 1 incomplete complete remission, and 1 reversion to chronic-phase chronic myelogenous leukemia.
  • Leukemic cell levels of topoisomerase I, checkpoint kinase 1, checkpoint kinase 2, and Mcl-1 correlated with proliferating cell nuclear antigen but not with response.
  • Responses seem to correlate with low pretreatment blast cell Bcl-2 expression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Aged. Bone Marrow Cells / drug effects. Bone Marrow Cells / metabolism. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carboplatin / pharmacokinetics. Cell Cycle Proteins / metabolism. Combined Modality Therapy. DNA Topoisomerases, Type I / metabolism. Dose-Response Relationship, Drug. Drug Resistance, Neoplasm. Female. HL-60 Cells. Hematopoietic Stem Cell Transplantation. Humans. Immunoblotting. Infusions, Intravenous. Male. Middle Aged. Neoplasm Recurrence, Local. Proliferating Cell Nuclear Antigen / metabolism. Topotecan / administration & dosage. Topotecan / adverse effects. Topotecan / pharmacokinetics. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166443.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA73709; United States / NCI NIH HHS / CA / U01 CA69854; United States / NCI NIH HHS / CA / U01 CA69912
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proliferating Cell Nuclear Antigen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down


88. Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A, Volin L, Gürman G, Maertens J, Bordigoni P, Holler E, Ehninger G, Polge E, Gorin NC, Kolb HJ, Rocha V, EBMT Acute Leukemia Working Party: Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol; 2007 Nov 1;25(31):4938-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
  • PURPOSE: To evaluate the role of donor lymphocyte infusion (DLI) in the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT).
  • Two-year survival was 56% +/- 10%, if DLI was performed in remission or with favorable karyotype, and 15% +/- 3% if DLI was given in aplasia or with active disease.
  • CONCLUSION: Although further evidence for a graft-versus-leukemia effect by DLI is provided, our results confirm, that the clinical benefit is limited to a minority of patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / therapy. Lymphocyte Transfusion. Neoplasm Recurrence, Local / therapy


89. Knüttgen D, Kamp M, Ströhlein M, Matten J, Chemaissani A, Ernestus K, Sakka SG, Wappler F: [Invasive pulmonary aspergillosis. Occurrence in a non-neutropenic female patient with abdominal sepsis]. Anaesthesist; 2009 Mar;58(3):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Invasive pulmonary aspergillosis. Occurrence in a non-neutropenic female patient with abdominal sepsis].
  • Invasive pulmonary aspergillosis (IPA) is a life-threatening infection predominantly affecting immunocompromised patients, e.g. with acute leukemia.
  • This case report demonstrates that IPA can also occur in non-neutropenic critically ill surgical patients.
  • The case of a 63-year-old woman is reported, who developed IPA of the respiratory tract in the course of diffuse purulent peritonitis.
  • However, application of caspofungin, intensive kinetic therapy (including prone position) and airway management by interventional bronchoscopy enabled successful treatment of this severe complication.

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2006 Oct;130(4):1143-9 [17035449.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2605-17 [14633632.001]
  • [Cites] Arch Intern Med. 1989 Jan;149(1):30-5 [2643417.001]
  • [Cites] Intensive Care Med. 2007 Oct;33(10):1694-703 [17646966.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Jun;34(2):293-313, viii [15850843.001]
  • [Cites] Clin Infect Dis. 2004 Dec 1;39(11):1563-71 [15578352.001]
  • [Cites] Microbiology. 1994 Sep;140 ( Pt 9):2475-9 [7952197.001]
  • [Cites] J Chemother. 2007 Jun;19(3):339-42 [17594932.001]
  • [Cites] Br J Radiol. 2001 Oct;74(886):955-8 [11675315.001]
  • [Cites] N Engl J Med. 2002 Aug 8;347(6):408-15 [12167683.001]
  • [Cites] Cancer. 2006 Dec 15;107(12 ):2888-97 [17103444.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Sep 15;170(6):621-5 [15229094.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Sep;98(9):718-20 [2675730.001]
  • (PMID = 19247622.001).
  • [ISSN] 1432-055X
  • [Journal-full-title] Der Anaesthesist
  • [ISO-abbreviation] Anaesthesist
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Lipopeptides; 0 / Pyrimidines; 0 / Triazoles; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole
  •  go-up   go-down


90. Kume T, Akasaka T, Kawamoto T, Watanabe N, Toyota E, Sukmawan R, Sadahira Y, Yoshida K: Visualization of neointima formation by optical coherence tomography. Int Heart J; 2005 Nov;46(6):1133-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our male patient, who had been treated with a coronary stent, died due to acute leukemia.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16394609.001).
  • [ISSN] 1349-2365
  • [Journal-full-title] International heart journal
  • [ISO-abbreviation] Int Heart J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Kim MK, Mun YC, Seong CM, Chung WS, Huh J: [Variant Philadelphia chromosome identified by interphase fluorescence in situ hybridization (FISH) without evidence on G-banded karyotyping and metaphase FISH]. Korean J Lab Med; 2010 Dec;30(6):711-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 52-year-old man was diagnosed with acute leukemia of mixed phenotype.
  • The other case was that of a 31-yr-old male patient diagnosed with CML in the blastic phase.
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 22. Chromosomes, Human, Pair 9. Humans. Interphase. Karyotyping. Leukemia / diagnosis. Leukemia / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Male. Metaphase. Middle Aged. Phenotype. Translocation, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157160.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


97. Bishop MM, Lee SJ, Beaumont JL, Andrykowski MA, Rizzo JD, Sobocinski KA, Wingard JR: The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. Biol Blood Marrow Transplant; 2010 Feb;16(2):207-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls.
  • Little is known about the health promotion, prevention, and disease screening behaviors of cancer survivors treated with hematopoietic cell transplantation (HCT), who undergo arduous treatment and may be at particular risk for late effects and secondary malignancies.
  • Some differences between disease group and type of transplant were found, with survivors of acute leukemia less likely to report regular exercise, autologous transplant survivors more likely than allogeneic transplant survivors to report screenings for breast and cervical cancer, and allogeneic transplant survivors more likely than autologous transplant survivors to report undergoing a skin exam in the previous year.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Healthy Aging.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):599-608 [15659507.001]
  • [Cites] Med Care. 1992 Jun;30(6):473-83 [1593914.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5814-30 [16043830.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8884-93 [16314649.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(3):249-61 [16435004.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Feb;12(2):138-51 [16443512.001]
  • [Cites] J Clin Oncol. 2006 Nov 10;24(32):5125-31 [17093274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):834-9 [17416780.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):2100-6 [17513816.001]
  • [Cites] Semin Oncol Nurs. 2007 Nov;23(4):242-52 [18022052.001]
  • [Cites] Blood. 2008 Jan 15;111(2):939-44 [17911386.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1073-9 [18309941.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Feb;6(2):215-22 [18319053.001]
  • [Cites] Oncol Nurs Forum. 2008 Mar;35(2):E12-22 [18321824.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2198-204 [18445845.001]
  • [Cites] Cancer. 2008 Jun;112(11):2475-82 [18428195.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3242-7 [18591559.001]
  • [Cites] J Cancer Surviv. 2007 Mar;1(1):17-26 [18648941.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):674-84 [10649263.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1712-9 [15386307.001]
  • [Cites] Am J Prev Med. 2005 May;28(4):351-6 [15831340.001]
  • (PMID = 19781657.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA081320-01; United States / NCI NIH HHS / CA / K23 CA082350-02; United States / NCI NIH HHS / CA / K23 CA082350; United States / NCI NIH HHS / CA / CA082350-01; United States / NCI NIH HHS / CA / CA081320-02; United States / NCI NIH HHS / CA / R01 CA081320-01; United States / NCI NIH HHS / CA / K23 CA082350-01; United States / NCI NIH HHS / CA / CA082350-05; United States / NCI NIH HHS / CA / K23 CA082350-04; United States / NCI NIH HHS / CA / CA082350-02; United States / NCI NIH HHS / CA / CA081320-03; United States / NCI NIH HHS / CA / K23 CA082350-05; United States / NCI NIH HHS / CA / R01 CA81320; United States / NCI NIH HHS / CA / K23 CA082350-03; United States / NCI NIH HHS / CA / CA082350-03; United States / NCI NIH HHS / CA / R01 CA081320-02; United States / NCI NIH HHS / CA / K23 CA82350; United States / NCI NIH HHS / CA / R01 CA081320; United States / NCI NIH HHS / CA / CA082350-04; United States / NCI NIH HHS / CA / R01 CA081320-03
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS148058; NLM/ PMC2819641
  •  go-up   go-down


98. Williams MV, Drinkwater KJ, Jones A, O'Sullivan B, Tait D: Waiting times for systemic cancer therapy in the United Kingdom in 2006. Br J Cancer; 2008 Sep 2;99(5):695-703
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, urgent treatment should be clearly defined as that required within 24 h (maximum 48 h) to avoid the risk of clinical deterioration, particularly in patients with acute leukaemia, lymphoma or germ cell tumour.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):492-6 [12888818.001]
  • [Cites] Breast Cancer Res Treat. 2006 Oct;99(3):313-21 [16583264.001]
  • [Cites] CMAJ. 2007 Jan 30;176(3):327-32 [17261829.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2007 Jun;19(5):273-86 [17517327.001]
  • [Cites] Radiother Oncol. 2008 Apr;87(1):3-16 [18160158.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):752-3 [17714992.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):784-96 [17714993.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):747 [17714994.001]
  • [Cites] J Thorac Oncol. 2007 Jul;2(7):590-2 [17607113.001]
  • (PMID = 18728658.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2528160
  •  go-up   go-down


99. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA: Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion; 2007 Nov;47(11):2153-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
  • BACKGROUND: Interpatient variability in the kinetics of peripheral blood progenitor cell (PBPC) mobilization is commonly seen with conventional chemotherapy-based mobilization regimens.
  • STUDY DESIGN AND METHODS: The efficacy of an approach where LP was invariably commenced on Day 11 after intermediate-dose cyclophosphamide followed by sequential administration of granulocyte-macrophage-colony-stimulating factor (CSF) and granulocyte-CSF (Cy/GM/G) was retrospectively analyzed in 225 consecutive, unselected patients undergoing autologous hematopoietic stem cell transplantation for all diagnoses other than acute leukemia at our center.
  • RESULTS: After Cy/GM/G, a CD34+ cell yield of at least 2.0x10(6) per kg was achieved in 90.7 percent of patients.
  • Optimal yield (OY; >or=5x10(6) or 10x10(6) CD34+ cells/kg depending on diagnosis) was achieved in 67.6 percent of patients.
  • PLT-D1LP and diagnosis of myeloma were associated with a shorter time to achieve a CD34+ cell yield of at least 5x10(6) per kg (p<0.001 and p=0.002, respectively).
  • CONCLUSION: Cy/GM/G with scheduled LP commencement on Day 11 enables optimal CD34+ cell yields in most patients undergoing autologous transplantation, despite a low risk of FN and avoidance of weekend LP.
  • [MeSH-major] Cyclophosphamide / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Leukapheresis
  • [MeSH-minor] Adult. Aged. Antigens, CD34. Female. Humans. Kinetics. Male. Middle Aged. Neutropenia. Peripheral Blood Stem Cell Transplantation / methods. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17958545.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


100. Xu B, Li L, Tang JH, Zhou SY: Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia. Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct;25(10):1207-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of FLT3 gene and FLT3/ITD mutation by polymerase chain reaction-single-strand conformation polymorphism in patients with acute lymphoblastic leukemia.
  • OBJECTIVE: To analyze Fms-like tyrosine kinase 3 (FLT3) gene and FLT3 internal tandem duplication (ITD) mutation in acute lymphoblastic leukemia (ALL) patients of different immunological subtypes.
  • Two cases (3.2%) were found to have FLT3/ITD mutation, which were also positive for myeloid antigen expression and diagnosed as acute mixed-lineage leukemia, showing leukocytosis and high percentage of bone marrow blast cells with poor prognosis.
  • In B-lineage ALL patients, FLT3 gene is more frequent in cases with undifferentiated than those with differentiated blast cells.
  • FLT3/ITD is rarely detected in ALL patients and FLT3/ITD mutation detection might be helpful to identify the genotypes and evaluate the prognosis of acute leukemia.
  • [MeSH-major] Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor Protein-Tyrosine Kinases / genetics. Tandem Repeat Sequences / genetics. fms-Like Tyrosine Kinase 3 / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234090.001).
  • [ISSN] 1000-2588
  • [Journal-full-title] Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA
  • [ISO-abbreviation] Di Yi Jun Yi Da Xue Xue Bao
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down